Formulation, Evaluation and Lyophilization of Cisplatin Loaded Liposomes by Rajaram, T
FORMULATION, EVALUATION   AND  LYOPHILIZATION 
OF CISPLATIN LOADED LIPOSOMES 
 
A Dissertation submitted to 
 
THE TAMIL NADU Dr.M.G.R. MEDICAL UNIVERSITY,  
CHENNAI - 32. 
 
In partial fulfillment of the requirements for the award of degree of 
 
MASTER OF  PHARMACY 
IN 
PHARMACEUTICS 
 
Submitted by 
 
Reg No.261510804 
 
Under the Guidance of  
Dr.S.CHANDRA, M.Pharm, Ph.D., 
Professor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF PHARMACEUTICS 
 
J.K.K.MUNIRAJAH MEDICAL RESEARCH FOUNDATION  
COLLEGE OF PHARMACY, KUMARAPALAYAM-638183.  
APRIL-2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATES 
 
                             CONTENTS 
 
SI. NO. TOPIC 
PAGE 
NO.   
   
1 INTRODUCTION 01 
   
2 LITERATURE REVIEW 37 
   
3 DRUG AND EXCIPIENTS PROFILE 43 
   
4 AIM AND PLAN OF WORK 52 
   
5 MATERIALS AND METHODS 55 
   
6 RESULTS 70 
   
7 DISCUSSION 108 
   
8 SUMMARY AND CONCLUSION 112 
   
9 BIBILOGRAPHY 115 
   
LIST OF TABLES 
 
Table 
              DESCRIPTION 
 
Page No.No.  
 
1 The most common glycerophospholipids 15 
    
2 Classification of liposomes 18   
    
3 List of chemicals used in the work 55   
   
4 List of equipments used in the work 56 
   
5 
The composition of Drug,  Soy Hspc, Cholesterol, Mpeg-dspe, 59 
Tocoferol and Ammonium sulphate.  
  
6 Standard Readings of Cisplatin in UV 70 
7   
7 Percentage correlations of drug and lipid mixtures 77 
   
8 particle size determination 80 
   
9 Zeta potential values of Cisplatin Liposomes 83 for optimized Batch.     
10 Percent Free Drug of Cisplatin Liposomal F1 to F6 Formulations. 89 
   
  
11 Assay of Cisplatin Liposomal F1 to F6 Formulations. 90 
   
   
12 
Diffusion results of F1 formulation 91 
   
   
13 
Diffusion results of F2 formulation 92 
   
   
14 
Diffusion results of F3 formulation 93 
   
   
15 
Diffusion results of F4 formulation 94 
   
   
16 
Diffusion results of F5 formulation 95 
   
   
17 
Diffusion results of F6 formulation  
  96 
  
18 Curve Fitting Data of Release Rate Profile of Formulations (F1 to 98 
 F6)   
   
19 
Effect of Temperature on Assay of Cisplatin at 4
O
C and room 107 
Temperature   
LIST OF FIGURES 
 
 
 
FIGURE     
NO. TITLE  PAGE NO.    
1 Structure of Liposome 09 
   
2 Shape of Phospholipids Molecule. 10 
   
3 General structure of cholesterol 17 
   
4 Preparation methods of liposomes 26 
  
5 Understanding Series of Cancer and Normal Cell 29 
   
6 Accumulation of Liposomes within Solid Tumors 32 
   
7 Standard Graph of Cisplatin in phosphate buffer pH 70  7.4     
    
8 FTIR of Cisplatin 71 
  
9 FTIR of Cisplatin and Hspc (1:1). 72 
    
10 FTIR of Cisplatin and Hspc (1:5). 72 
    
11 FTIR of Cisplatin and Hspc (5:1). 73 
   
12 FTIR of Cisplatin and Cholesterol (1:1). 73 
  
13 
FTIR of Cisplatin and Cholesterol (1:5). 
74 
 
   
14 FTIR of Cisplatin and Cholesterol (5:1). 74 
   
15 FTIR of Cisplatin and mpeg-dspe (1:1). 75 
   
16 FTIR of Cisplatin and mpeg-dspe (1:5). 75 
   
17 FTIR of Cisplatin and mpeg-dspe (5:1). 76 
  
18 D.S.C of Cisplatin 78 
  
19 D.S.C of Cisplatin, Hspc , Cholesterol and 79  Mpeg-dspe     
     
 S.NO. TITLE 
PAGE NO. 
 
   
20 Particle size distribution of cisplatin F2 liposomal 81 Formulation    
   
21 
Particle size distribution of cisplatin F6 liposomal 82 
Formulation    
   
22 Zeta potential for Cisplatin Liposomal F2 formulation 84   
   
23 Zeta potential for Cisplatin Liposomal F6 formulation 85   
   
24 TEM images of cisplatin liposomes 86   
   
25 SEM images of Cisplatin liposomes 87
   
26 In-vitro drug release of F1 to F6 Formulations 98 
   
27 Release kinetics from F1 Formulation 99
   
28 Release kinetics from F2 Formulation 100 
   
29 Release kinetics from F3 Formulation 101 
  
30 Release kinetics from F4 Formulation 102 
  
31 Release kinetics from F5 Formulation 103 
   
32 Release kinetics from F6 Formulation 104
   
33 Lyophilization process 105 
   
34 Lyophilized formulation of liposomes 106   
  
LIST OF SYMBOLS/ABBREVIATIONS 
 
 
 
       AUC Area under curve 
 
      AVE Artificial viral envelopes 
 
CDR Cumulative Drug Release 
 
CDRR Cumulative drug release remaining 
 
CONC Concentration 
 
DNA De oxy ribose nucleic acid 
 
DSPC Distearoyl phosphatidyl choline 
 
EE Encapsulation efficiency 
 
FTIR Fourier Transform Infrared 
 
GUV Gaint unilamellar vesicles 
 
gm Gram 
 
HPLC High performance liquid chromatography 
 
IPA Iso propyl alchol 
 
IR Infrared spectroscopy 
 
KS Kaposis sarcoma 
 
LUV Large unilamellar vesicles 
 
MLV Multi laminar vesicles 
 
MPS Mononuclear phagocytic system 
 
MVV Multi vesicular vesicles 
 
 
NDDS Novel Drug Delivery System 
 
OLV Oligolamellar vesicles 
 
PBS Phosphate buffer saline 
 
PC Phosphatidyl choline 
 
PDI Poly dispersive index 
 
PEG Polyethylene glycol 
 
RES Reticulo Endothelial system 
 
RNA Ribonucleic acid 
 
RPM Rotations per minute 
 
SEM Scanning Electron Microscopy 
 
SUV Small unilamellar vesicles 
 
TEM Transmission electron microscopy 
 
USP United States Pharmacopoeia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Chapter No: 1 Introduction 
 
 
INTRODUCTION 
 
1. INTRODUCTION TO TARGETED DRUG DELIVERY SYSTEMS 
 
 
The concept of designing specified delivery system to achieve selective drug 
targeting has been originated from the perception of Paul Ehrlich, who proposed drug 
delivery to be as a “magic bullet”. 
 
Controlled & Novel drug delivery envisages optimized drug delivery in the sense 
that the therapeutic efficacy of a drug is optimized, which also implies nil or minimum 
side effects. It is expected that the 21st century would witness sea changes in the area of 
drug delivery. The products may be more potent as well as safer. Target specific drug 
delivery is likely to overcome much of the criticism of conventional dosage forms. The 
cumulative outcome could be summarized as optimized drug delivery that encompasses 
greater potency & greater effectiveness, lesser side effects and toxicity, better stability, 
low cost hence greater accessibility, ease of administration and best patient compliance. 
 
 
1.1 RATIONALE OF DRUG TARGETING1 
 
 
 
The site-specific targeted drug delivery negotiates an exclusive delivery to 
specific pre identified compartments with maximum intrinsic activity of drugs and 
concomitantly reduced access of drug to irrelevant non-target cells. The controlled rate & 
mode of drug delivery to pharmacological receptor and specific binding with target cells; 
as well as bioenvironmental protection of the drug in route to the site of action are 
specific features of targeting. Invariably, every event stated contributes to higher drug 
concentration at the site of action and resultant lowers concentration at non-target tissue 
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where toxicity might crop-up. The high drug concentration at the target site is a result of 
the relative cellular uptake of the drug vehicle, liberation of drug and efflux of free drug 
from the target site. Targeting is signified if the target compartment is distinguished from 
the other compartments, where toxicity may occur and also if the active drug could be 
placed predominantly in the proximity of target site. The restricted distribution of the 
parent drug to the non-target site(s) with effective accessibility to the target site(s) could 
maximize the benefits of targeted drug delivery. 
 
 
1.1.1 APPROACHES1,2 
 
The various approaches of vectoring the drug to the target site can be broadly 
Classified as: 
 
• Passive targeting 
 
• Inverse targeting 
 
• Active targeting (Ligand mediated targeting and Physical targeting) 
 
• Dual targeting 
 
• Double targeting 
 
• Combination targeting   
 
¾ PASSIVE TARGETING: 
 
 
Systems that target the systemic circulation are generally characterized as 
 
“passive” delivery systems (i.e., targeting occurs because of the bodys natural response 
to the physiochemical characteristics of the drug or drug-carrier system. It is a sort of 
passive process that utilizes the natural course of (attributed to inherent characteristics) 
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bio distribution of the carrier system through which, it eventually accumulate in the organ 
compartment(s) of body. The ability of some colloids to be taken up by the RES 
especially in liver and spleen has made them as ideal vectors for passive hepatic targeting 
of drugs to these compartments. This category of targetable devices includes drug bearing 
bilayer vesicular systems as well as cellular carriers of micron or sub micron size range. 
 
 
 
¾
 INVERSE TARGETING: 
 
It is essentially based on successful attempts to circumvent and avoid passive uptake 
of colloidal carriers by reticuloendothelial system (RES). This effectively leads to the 
reversion of bio distribution trend of the carrier and hence the process is referred to as 
inverse targeting. One strategy applied to achieve inverse targeting is to suppress the 
function of RES by pre-injection of a large amount of blank colloidal carriers or 
macromolecules like dextran sulphate. This approach leads to RES blockade and as a 
consequence impairment of host defense system. Alternate strategies include 
modification of the size, surface charge, composition, surface rigidity and hydrophilicity 
of carriers for desirable biofate. 
 
 
 
¾
 ACTIVE TARGETING: 
 
Conceptually, active targeting exploits modification or manipulation of drug carriers 
to redefine its biofate. The natural distribution pattern of the drug carrier composites is 
enhanced using chemical, biological and physical means, so that it approaches and is 
identified by particular biosites. The facilitation of the binding of the drug-carrier to 
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target cells through the use of ligands or engineered homing devices to increase receptor 
mediated (or in some cases receptor independent but epitopes based) localization of the 
drug and target specific delivery of drug(s) is referred to as active targeting. This 
targeting approach can further be classified into three different levels of targeting: 
 
 
(i)First Order Targeting: It refers to restricted distribution of the drug-carrier system to 
the capillary bed of a predetermined target site, organ or tissue. Compartmental targeting 
in lymphatic, peritoneal cavity, plural cavity, cerebral ventricles, lungs, joints, eyes, etc., 
represents first order targeting (it could also be categorized as a level of passive 
targeting). 
 
 
(ii)Second Order Targeting: The selective delivery of drugs to a specific cell type such 
as tumor cells and not to the normal cells is referred as second order drug targeting. The 
selective drug delivery to the Kupffer cells in the liver exemplifies this approach. 
 
 
(iii)Third Order Targeting: The third order targeting is defined as drug delivery 
specifically to the intracellular site of target cells. An example of third order targeting is 
the receptor based ligand-mediated entry of a drug complex into a cell by endocytosis, 
lysosomal degradation of carrier followed by release of drug intracellularly or gene 
delivery to nucleolus. 
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¾
 LIGAND MEDIATED TARGETING: 
 
Targeting components, which have been studied and exploited are pilot molecules 
themselves (bioconjugates) or anchored as ligands on some delivery vehicle (drug-carrier 
system). All the carrier systems, explored so far, in general, are colloidal in nature. They 
can be specifically functionalized using various biologically relevant molecular ligands 
including antibodies, polypeptides, oligosaccharides (carbohydrates), viral proteins and 
fusogenic residues. The ligands afford specific avidity to drug carrier. The engineered 
carrier constructs selectively deliver the drug to the cell or group of cells generally 
referred to as target. 
 
The cascade of events involved in ligand negotiated specific drug delivery is termed 
as ligand driven receptor mediated targeting. 
 
 
¾
 PHYSICAL TARGETING (Triggered Release): 
 
The selective drug delivery programmed and monitored at the external level (ex 
vivo) with the help of physical means is referred to as physical targeting. In this mode of 
targeting, some characteristics of the bioenvironmental are used either to direct the carrier 
to a particular location or to cause selective release of its content. 
 
 
¾
 DUAL TARGETING: 
 
This classical approach of drug targeting employs carrier molecules, which have 
their own intrinsic antiviral effect thus synergizing the antiviral effect of the loaded active 
drug. Based on this approach, drug conjugates can be prepared with fortified activity 
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profile against the viral replication. A major advantage is that the virus replication 
process can be attacked at multiple points, excluding the possibilities of resistant viral 
strain development. 
 
¾
 DOUBLE TARGETING: 
 
For a new future trend, drug targeting may be combined with another methodology, 
other than passive and active targeting for drug delivery systems. The combination is 
made between spatial control and temporal control of drug delivery. The temporal control 
of drug delivery has been developed in terms of control drug release prior to the 
development of drug targeting. If spatial targeting is combined with temporal control 
release results in an improved therapeutic index by the following two effects. First, if 
drug release or activation is occurred locally at therapeutic sites, selectivity is increased 
by multiplication of the spatial selectivity with the local release/activation. Second, the 
improvement in the therapeutic index by a combination of spatially selective delivery and 
a preferable release pattern for a drug, such as zero order release for a longer time period 
of the drugs. When these two methodologies are combined, it may be called 
 
“Double targeting” 
 
 
 
¾
 COMBINATION TARGETING: 
 
Petit and Gombtz, 1998 have suggested the term combination targeting for the site-
specific delivery of proteins and peptides. These targeting systems are equipped with 
carriers, polymers and homing devices of molecular specificity that could provide a direct 
approach to target site. Modification of proteins and peptides with natural polymers, such 
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as polysaccharides, or synthetic polymers, such as poly (ethylene glycol), may alter their 
physical characteristics and favor targeting the specific compartments, organs or their 
tissues within the vasculature. 
 
 
1.1.2 LIMITATIONS OF TARGETED DELIVERY SYSTEMS 3 
 
Several problems have been identified which require alterations in targeting 
 
Strategies particularly, in- vivo. These include: 
 
• Rapid clearance of targeted systems especially antibody targeted carriers. 
 
• Immune reactions against intravenous administered carrier systems. 
 
• Target tissue heterogeneity 
 
• Problems of insufficient localizations of targeted systems into tumor cells. 
 
• Down regulation and sloughing of surface epitopes. 
 
• Diffusion and redistribution of released drug leading to no-specific accumulation.     
1.1.3 CARRIERS USED IN TARGETED DRUG DELIVERY SYSTEMS.4,5,6 
 
Carrier is one of the most important entities essentially required for successful 
 
transportation of the loaded drug(s). They are drug vectors, which sequester, transport 
and retain drug en route, while elute or deliver it within or in vicinity of target. 
 
 
(I)Colloidal carriers: 
 
(a) Vesicular systems: Liposomes; Niosomes; Pharmacosomes; Virosomes; 
 
Immunoliposomes. 
 
(b) Micro particulate systems: Microparticles; Nanoparticles; Magnetic microspheres; 
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Nanocapsules. 
 
(ii)Cellular carriers 
 
Resealed erythrocytes; serum albumin; antibodies; platelets; leukocytes. 
 
(iii)Cellular delivery systems 
 
Micelles; reverse micelles; mixed micelles; polymeric micelles; liquid crystal; 
lipoproteins (chylomicron; VLDL; LDL) synthetic LDL mimicking particles 
(Supramolecular biovector system) 
 
(iv)Polymer based systems 
 
Signal sensitive; muco-adhesive; biodegradable; bioerodible; solute synthetic 
 
polymeric carriers. 
 
(v)Macromolecular carriers 
 
Proteins, glycoproteins; neo glycoproteins and artificial viral envelopes 
(AVE) Glycosylated water-soluble polymers (poly-L-lysine) 
 
Mabs; Immunological Fab fragments; antibody enzyme complex & bispecific 
Abs Toxins, immunotoxin & rCD4 toxin conjugates 
 
Lectins (Con A) & polysaccharides. 
 
 
 
 
1.2 LIPOSOMES7 
 
Liposomes are concentric bilayered vesicles in which an aqueous volume 
is entirely enclosed by a membranous lipid bilayer. Liposomes were discovered by A. 
Bangham and his team about 45 years ago and ever since then they developed into 
versatile tools in biology, medicine and biochemistry. Liposomes are the smallest 
artificial vesicles of spherical shape that can be produced from natural untoxic 
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phospholipids and cholesterol. Liposomes can be defined as a particular kind of vesicles 
or any structure formed by lipid bilayers which are capable to enclose a volume of the 
substance. 
 
Liposomes are microscopic vesicles with diameter between 20nm to 
20µm, which consist of one or more concentric bilayers phospholipids surrounding an 
aqueous membrane. When phospholipids are dispersed in an aqueous medium, liposomes 
form spontaneously as a result of interaction of water and phospholipid molecules which 
are amphiphilic i.e. they possess hydrophilic and hydrophobic regions. This allows a 
wide range of materials to be incorporated since hydrophilic drugs are entrapped in the 
aqueous region and hydrophobic materials are located in the hydrophobic regions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
Figure No: 1 Structure of liposome 
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Figure No. 2 Shape of phospholipids molecule 
 
 
 
 
 
 
1.2.1 LIPOSOMES DELIVERED INTERCELLULARLY8 
 
 
 
Liposomes deliver their contents to the cytoplasm of cells in culture either by 
fusion with the outer cell membrane or by endocytosis where upon they are concentrated 
in acidic lysozymal sacs. 
 
 
1) Inter membrane transfer 
 
 
 
 
Inter membrane transfer of lipid component can take place upon close approach 
of the two phospholipid bilayers without the need for disruption of the 
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liposome. Only specific phospholipids exchange (PC &PE) via intermediate of a specific 
cell surface exchange protein. Similarly Liposomes and lipoproteins (HDL) interactions 
is important liposomal stability in circulation. Addition of cholesterol retards immediate 
destabilization of Liposomes. 
 
2) Contact release 
 
 
 
 
The liposome content with cell causes an increase in permeability on the 
entrapped content through bilayer membrane, curiously, cell induced leakage of solutes 
have been observed to be greater in membranes with cholesterol concentration above 
30%. This process strengthened by means of receptor/ligand between the two 
membranes. 
 
 
 
3) Adsorption 
 
 
 
 
The adsorption of Liposomes takes place either as a result of physical 
attractive forces, or as a result of binding by specific receptors to ligands on the vesicle 
membranes. The attraction depends on the specific cell surface protein. This interaction 
was more in case of gel phase of liposome. 
 
 
4) Fusion 
 
 
 
 
Close approaching of Liposomes and cell membranes can lead to fusion of the 
two resulting in complete mixing of liposomal lipids with those of the plasma membrane 
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of the cell and the liposomal content released in to cytoplasm. This process takes place 
after phagocytosis and endocytosis of Liposomes. Inside the Endosome, Liposomes were 
affected by acidic pH. There by this will completely fuse and deliver the drug content in 
to cytoplasm. 
 
 
1.2.2 STABILITY OF LIPOSOMES.9,10 
 
 
 
The stability of Liposomes is of major concern in their development for 
pharmaceutical applications. A drug containing Liposomes can be unstable because of 
physical or chemical stability. The stability studies could be broadly covers under two 
main sections. 
 
Stability in-vitro mainly covers the stability aspects prior to the 
administration of the formulation and with regard to the stability of the constituted lipids. 
 
Stability invivo, which covers the stability aspects once the formulation, is 
administered via various routes of biological fluids. 
 
 
1.3 COMPOSITION 
 
1.3.1. Phospholipids. 10,11,12 
 
 
Phospholipids are the main component of naturally occurring 
bilayers. These phospholipids include phosphatidylcholines (PC), 
phosphatidylethanolamines (PE) and phosphatidylserines (PS]. The key common feature 
that bilayer-forming compounds share is their amphiphilicity i.e., they have defined polar 
and non-polar regions. This is the reason the non-polar regions orientate themselves 
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towards the interior away from the aqueous phase, the polar regions being in contact with 
it . 
 
The phospholipid composition and the capability of binding to other 
chemical species is one of the main features of their use in liposome formation (Rachev 
et al., 2001; Gomez-hens and Fernandez-Romero, 2005). Phospholipids are part of all 
cell membranes and play an important role in the signal transduction mechanism. The 
phospholipid structure consists of phosphoric residue, hydrophilic head and hydrophobic 
tail. The hydrophilic head consists of the phosphate group, glycerol back bone, choline, 
ethanolamine and inositol, with different chemical properties. When exposed to an 
aqueous environment, phospholipids tend to form unique assemblies called "bilayers". 
The hydrophilic heads of the phospholipids turn towards the water molecules while the 
hydrophobic tails hide from water molecules. 
 
There are two basic sources of phospholipids: synthetic and natural. 
Natural lipids are generally either egg-derived or bovine-derived. Regardless of the 
regulatory issues, animal-derived products do not offer any advantages to synthetic lipids. 
They are inherently less stable due to the polyunsaturated fatty acids, and in most cases 
the synthetic counterpart costs the same or less than the tissue-derived product. Synthetic 
lipids from different sources are not necessarily equal either. Synthetic lipids can be 
prepared from glycerol or glycero-3-phosphocholine (GPC) derived from a plant or 
animal source. The latter is sometimes referred to as semi-synthetic lipid because a 
portion of the molecule is derived from a natural source. Lipids derived from glycerol 
require the chiral centre be synthetically prepared which may lead to stereo chemical 
impurities present in the final product. 
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The typical plant source for GPC is soybean lecithin. This type of 
compound is synthesized by converting a natural PC into an acyl group through a 
chemical reaction. A highly pure, high-quality hydrogenated soy phospholipids that can 
assist you in developing new products is generally obtained from carefully selected, non-
genetically modified soybeans as a source of raw materials. 
 
There are five main groups of phospholipids that are available that 
can be used for liposome preparation. 
 
1. Phospholipids from natural sources. 
 
 
2. Phospholipids modified from natural sources. 
 
 
3. Semi-synthetic phospholipids. 
 
 
4. Fully-synthetic phospholipids, 
 
 
5. Phospholipids with non-natural head groups 
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Table No 1: The most common glycerophospholipids 
 
 
The esterified Name of the Abbreviation Net charge on 
group Phospholipid  pH 7 
    
-H Phosphotidicacid PA Negative
    
-CH2CH2N
+(CH3)3 Phosphotidylcholin PC Zwitterionic
    
-CH2CH2NH3
+ 
Phosphotidylethanolamine PE Zwitterionic
    
-CH2CHNH3
+COO- Phosphotidylserine PS Negative
    
-CH2CHOHCH2OH Phosphotidylglycerol PG Negative
    
-HC6H5(OH)5 Phosphotidylinositol PI Negative
    
 
 
 
The charge of the lipid used in liposome formation dictate the surface charge of 
the liposomes. The surface charge of liposomes can be tailored by replacing phosphatidyl 
choline (PC) partly with negatively or positively charged (phospho)lipids (Table 1.1), 
which induces electrostatic repulsion and stabilization against liposome fusion. The 
surface characteristics of liposomes may also be altered by modifying lipids with 
hydrophilic moieties e.g. polyethylene glycol (PEG) to membrane bilayers. 
 
1.3.2. STEROIDS14 
 
 
Cholesterol, is an alternative habitual component of the liposome structure and a 
natural constituent of the biological membranes, whereas stearic acid is a saturated form 
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of fatty acid, cholesterol and stearic acid play an important role in controlling the fluidity 
and the permeability of the artificial vesicle i.e. it makes the membranes more rigid thus 
avoiding leakage of the encapsulated compound. In order to improve the rigidity of the 
liposome, cholesterol and stearic acid were combined with other phospholipids to form 
liposome formulations. Cholesterol incorporation increases the separation between the 
choline head group and eliminates the normal electrostatic and hydrogen bonding 
interactions. Its inclusion in liposomal membrane has three recognized effects31. 
 
1. Increasing the fluidity or micro viscosity of the bilayer. 
 
 
 
 
2. Reducing the permeability of the membrane to water-soluble molecules. 
 
 
 
 
3. Stabilizing the membrane in the presence of biological fluids such as plasma. 
 
 
 
 
Liposomes without cholesterol are known to interact rapidly with plasma 
proteins such as albumin, transferrin and micro globulins. These proteins tend to 
extract bulk phospholipids from liposomes, thereby depleting the outer most layer of 
the vesicles leading to physical instability. 
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Figure No:3 General Structure Of Cholesterol (Chol) 
 
 
1.4. CLASSIFICATION OF LIPOSOMES15 
 
 
(A) Based on structural parameters: 
 
 
 
 
Liposomes can be classified by the number of bilayers present. Single bilayers 
(lamella) liposomes are called unilamellar vesicles (ULVs), while liposomes containing 
more than one bilayer are multilamellar vesicles (MLVs). Other liposomes consisting of 
small vesicles incorporating large vesicle are known a multivesicular vesicles (MVVs) 
(Gomez-hens and Fernandez-Romero, 2005). The entrapment of active compounds also 
depends on the different sizes of liposomes ranging from nanometer (nm) to micrometer 
 
(μm), such as small unilamellar vesicles (SUVs, 25-50 nm), large unilamellar vesicles 
(LUVs, 100 nm-1 μm), giant unilamellar vesicles (GUVs, 1.0-200 μm), multilamellar 
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vesicles (MLVs, 0.1-15 μm), and multi-vesicular vesicles (MVVs, 1.6-10.5 μm) (Silva et 
al., 2010). Liposomes can usually be stored in a buffer at pH 7.4 and at temperature 
approximately 4 °C for 5-7 days. 
 
Vesicle types Abbrev Diameter Number   of   lipid 
  Size bilayers 
    
Small unilamellar vesicles SUV 20-100nm One lipid bilayer 
    
Large unilamellar vesicles LUV >100nm One lipid bilayer 
    
Multi lamellar vesicles MLV >0.5nm 5-20 lipid bilayers 
    
Oligolalamellar vesicles OLV 0.1-1nm Approximately 5 lipid
   bilayers 
    
Multivescular vesicles MMV >1µm Multi  compartmental
   structure 
    
Table No:2 Classification of liposomes   
 
 
 
 
 
(B) Based on method of preparation 
 
 
 
 
(1) Single or oligolamellar vesicles made by reverse phase evaporation. 
 
(2) Multilamellar vesicles made by the reverse phase method. 
 
(3) Stable plurilamellar vesicles. 
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(4) Frozen and thawed multilamellar vesicles. 
 
(5) Vesicles prepared by extrusion method. 
 
(6) Vesicles prepared by French press. 
 
(7) Vesicles prepared by fusion. 
 
(8) Dehydration-rehydration vesicles. 
 
 
 
 
(C) Based on materials used for preparation: 
 
 
 
 
(1) Conventional liposomes 
 
 
 
 
• Stabilized natural lecithin or phosphatidyl choline (PC) mixtures. 
 
• Synthetic identical-chain phospholipids. 
 
• Glycolipid containing liposomes.     
(2) Specialty liposomes 
 
• Bipolar fatty acids 
 
• Antibody directed 
 
• Methyl/Methylene linked 
 
• Lipoprotein coated 
 
• Carbohydrate coated 
 
• Multiple encapsulated 
 
• Emulsion compatible 
 
 
 
 
 
Dept. of Pharmaceutics,       JKKMMRF College of pharmacy  
19 
Chapter No: 1 Introduction 
 
 
(D) Based upon composition and applications: 
 
 
 
 
(1) Conventional liposomes: Neutral or negatively charged phospholipids and 
Cholesterol. 
 
(2) Fusogenic liposomes: Reconstituted sendai virus envelopes. 
 
(3) Cationic liposomes: Cationic lipids with dioleoyl phosphotidyl ethanolamine 
(DOPE). 
(4) Long circulatory: Neutral high T0C, cholesterol and (stealth) liposomes 5-10% of 
Poly ethylene glycol-distearoyl ethanolamine (PEG-DSPE). 
 
(5) Immuno liposomes: conventional liposomes (CL) or long circulating liposomes 
(LCL) with attached monoclonal antibody or recognition sequence 
 
 
 
1.5 THE ROLE OF LIPOSOME SIZE16, 17 
 
 
The rate of the opsonisation and clearance by the reticuloendothelial system 
(RES) of the injected liposomes from the blood circulation is dependent on the 
composition and size. RES is part of the immune system and their main function is to 
eliminate foreign materials from the body. RES consists of cells such as blood monocytes 
and macrophages found mainly in the Kupffer cells in liver, the lung and the spleen. 
Shortly after i.v injection, the liposomes become coated by serum proteins called 
opsonins. Once they are opsonised, they will rapidly be phagocyted by the RES cells, and 
the major part of the injected liposomes will be accumulated in the liver and spleen 
(Maurer et al., 2001). Large liposomes (>200 nm in diameter) are rapidly opsonised and 
taken up by the (RES) disappear from the blood circulation within short time and 
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primarily end up in the spleen. Opsonisation decreases with a decreasing in liposome 
size. 
 
Small liposomes have a relatively larger surface area, and will have a lower 
density of opsonins on the membrane surface which results in lower uptake by the 
macrophages. Liposomes with a size of 70 to 200 nm will have a greater chance to escape 
from RES and remain in the circulation longer and then reach the target. Due to 
extravasations through the fenestrated capillary walls in the liver, the small liposomes (< 
70 nm in diameter) show shorter circulation time. The structure and architecture of the 
blood capillary walls varies in different organs and tissues. There are structure 
differences between healthy and tumour capillaries and blood supply to the organs and 
tissues is somewhat different . 
 
1.6 THE ROLE OF SURFACE CHARGE AND MEMBRANE 
 
CHARACTERESTICS18, 19 
 
 
 
Lipid organization in the liposome membranes has a major role on the physical 
membrane properties such as permeability, membrane elasticity, surface charge and 
binding properties of proteins, and is of equal importance for clearance as compared to 
liposome size. Neutral charged liposomes with tightly packed membranes tend to remain 
longer in the circulation and exhibit increased drug retention, compared to charged 
systems. Protein opsonisations onto the liposome surface are reduced due to the tightly 
packed and rigid membrane. The presence of Chol in liposome formulations may change 
the packing of the phospholipids to a more ordered and rigid membrane and may stabilize 
to avoid drug leakage. Moreover, this may reduce binding of opsonins on the liposomes 
 
Dept. of Pharmaceutics,       JKKMMRF College of pharmacy  
21 
Chapter No: 1 Introduction 
 
 
and may improve stability and retention of liposomes in vivo. Certain plasma proteins 
have an affinity for liposomes, and the affinity is enhanced if the liposome is charged. In 
particular cationic systems are expected quickly interaction with various components in 
systemic circulation and thus having shorter half life in vivo. It is also known that anionic 
liposomes containing negatively charged lipids such as phospatidylserine (PS), 
phosphatidicacid (PA) and phosphatidylglycerol (PG) are quickly taken up by 
macrophages and thus disappear from the circulation in short time. 
 
 
 
1.7 APPLICATIONS OF LIPOSOMES20, 21 
 
 
Liposomes are mainly used as delivery systems for many substances which 
can easily be entrapped or act as anchor to various substituents. Liposomal delivery 
systems are well-known procedures used for encapsulation of anticancer and 
antimicrobial drugs, enzymes and antigens. The Application of Liposomes in the delivery 
systems aid in processes such as transport, distribution, controlled release, protection and 
localization of encapsulated drugs. 
 
 
In order to improve the performance of the enclosed drug, it is useful to consider the 
basic reasons for applying liposome as drug carriers. 
 
1. Liposomes act as carriers for drug both in vitro and in vivo. 
 
2. In targeted delivery system, liposomes are used as carriers for anticancer 
drugs such as methotrexate, actinomycin-D etc. 
 
3. Liposomes encapsulation has been used as a step in enzyme purification. 
 
4. The use of liposomes as encapsulated insulin and growth hormone for oral 
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administration has been reported. 
 
5. The most important use of liposomes in cell biology is to manipulate the 
status of membrane lipid. 
 
6. Liposomes can be used to insert important regulatory molecules such 
as CGMP,CAMP and enzymatic cofactors into cells. 
 
7. Liposome collagen gels show slow release of a variety of bioactive drugs 
into the circulation thus having an obvious advantage over multiple dosage 
regimens. 
 
8. This technique may also have topical application in the treatment of 
wounds and burn. 
 
9. Inclusion of antimicrobials or cells growth factors within the liposomes can 
facilitate enhanced cell growth and prevention of infection. 
 
10. As research tool for modeling those cellular functions, which are 
determined at the membrane level. 
 
11. In the field of micro analysis (membrane immuno assay). 
 
12. Liposomes are used as carriers of radiopharmaceuticals for 
diagnostic imaging. 
 
13. Used industrially in the rapidly developing field of recombinant 
DNA technology for the synthesis of exotic chemicals and drugs. 
 
14. Applications in cosmetics. 
 
Liposomes are used as carriers of substances such as natural moisturizing 
 
factor (NMF), alpha hydroxyl acid (AHA), proteins, vitamins (A and E), 
 
oils, phytosterols and antioxidants. 
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15. Liposomes in gene delivery: 
 
• Gene and antisense therapy. 
 
• Genetic(DNA)vaccination. 
 
16. Liposomes in immunology 
 
• Immunoadjuvant 
 
• Immunomodulator 
 
• Immunodiagnostic 
 
17. Liposomes as artificial blood surrogates 
 
 
 
 
1.8 METHODS OF PREPARATION20,21 
 
 
 
There are several methods to prepare liposomes each depending on the type of 
liposome desired (SUV, MLV or LUV). Some commonly used procedures are: 
 
1. Thin film hydration 
 
2. Sonication 
 
3. Extrusion 
 
4. French pressure 
 
5. Injection of water immiscible solvent 
 
• Ether injection 
 
• Fluorocarbon injection 
 
6. Injection of water miscible solvents 
 
• Ethanol injection 
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7. By alternative water miscible solvents 
 
8. By pH adjustment 
 
9. Detergent Dialysis method 
 
• Dialysis 
 
• Column chromatography 
 
• Centrifugation 
 
• Bio-beads 
 
• Reverse phase evaporation 
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Methods of 
preparation 
of liposomes 
 
 
 
 
 
 
Passive loading Active loading 
techniques techniques 
 
 
 
 
 
 
 
Mechanical 
Solvent dispersion Detergent removal 
dispersion methods Methods methods  
 
 
 
 
 
 
 
• Lipid film  • Ethanol  •  Detergent(cholate 
 hydration by   Injection  ,  
 hand shaking,  • Ether injection  alkylglycosides,tr 
 non-hand  • Double  iton-X100) 
 shaking or   emulsion  removal from
• 
freeze drying  • Reverse phase  mixed micelles
Micro-   evaporation  by  
 emulsification   Vesicles  ¾ Dialysis  
• Sonication  • Stable pluri  ¾ Dilutions  
• French   lameller vesicle  ¾ Column  
 pressure cell chromatography
• Membrane     ¾ Reconstituted 
      sendai virus
 
Fig.no 4 Liposomes preparation methods. 
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1.9 MECHANISM OF LIPOSOME FORMATION23 
 
 
In order to understand why liposomes are formed when phospholipids are 
hydrated, it requires a basic understanding of psycho-chemical features phospholipids. 
 
Phospholipids are amphipathic (having affinity for both aqueous and polar 
moieties) molecules as they have a hydrophobic tail and a hydrophilic or polar head. In 
aqueous medium the molecules in self-assembled structures are oriented in such a way 
 
that   the   polar portion of the molecule remains in   contact with   the   polar
environment  and at  the same time  shields  the non-polar part. Molecules  of
 
phosphatidyl choline (PC) are not soluble (rather dispersible) in aqueous medium in the 
physical chemistry sense, as in aqueous media they align themselves closely in planer 
bilayer sheets to minimize the unfavorable interactions between the bulk aqueous phase 
 
and long hydrocarbon fatty acyl chain. Such interactions are completely eliminated 
 
when the sheets fold over themselves to form closed, sealed and concentric vesicles. 
Phosphatidylcholine preferably orient to form bilayer sheets rather than micellar 
structures. Lipid vesicles are formed when thin lipid films or lipid cakes are hydrated and 
stacks of liquid crystalline bilayers become fluid and swell. The hydrated lipid sheets 
detach during agitation and self close to form large, multilameller vesicles (MLVs). Once 
these vesicles are formed, a change in the vesicle shape and morphology requires energy 
input in the form of sonic energy (sonication to get small unilamellar vesicles, SUVs) and 
mechanical energy (extrusion to get large unilamellar vesicles, LUVs). 
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1.9.1 Rigidization of fluid phase vesicles with cholesterol: 
 
 
Cholesterol acts as “Fluidity buffer” since below the phase trans ition it tends to 
make the membrane less ordered while above the transition it tends to make the 
membrane more ordered, thus suppressing the tilts and shift in membrane structure 
specifically at the phase transition. Though cholesterol itself does not form bilayers, but it 
can be incorporated into phospholipid membrane in very high concentrations up to 1:1 or 
even 2:1 molar ratio of cholesterol to PC. Being an amphipathic molecule, cholesterol 
inserts into the membrane with its hydroxyl group oriented towards the aqueous surface 
and the aliphatic chain aligned parallel to acyl chains in the center of the bilayer. This 
could be the possible mechanism for phospholipid membranes with high levels of 
cholesterol that retard the chain tilt. 
 
 
1.10 CANCER CHEMOTHERAPY22 
 
Cancer (Sydney. Basic clinical pharmacology (3
rd
 edition)) is a group of 
neoplastic diseases that occur in human of all age groups and races as well as in all 
animals species. The incidence, geographic distribution and behavior of specific types of 
cancer are related to multiple factors include sex, age, race, genetic predisposition and 
exposure to environmental carcinogen. 
 
Cancer is a disease of uncontrolled cell division, invasion and metastatic. It is 
generally considered to be due to the clonal expansion of a singe neoplastic cell. 
However there may be additional somatic leading to heterogeneous cell population. 
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Fig No:5  Understanding series of Cancer and normal Cell division   
    
    
    
 
 
 
 
 
Cancer chemotherapy has been under intensive development for the past 30 
years, resulting in cures of certain types of disseminated cancers that were previously 
fatal. Even patients with advanced disease have improved dramatically with 
chemotherapy. 
 
 
Mode of action of chemotherapeutics 
 
 
 
 
Most antineoplastic agents are regarded as “cell-cycle specific”. They act 
specifically on processes such as DNA synthesis, transcription, or the function of 
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mitotic spindle. 
 
All slow growing and fast growing tumor cells display a similar pattern 
 
during the division. This may be characterized as follows: 
 
 
 
 
1. There is pre synthetic phase 
 
2. The synthesis of DNA occurs 
 
3. An interval follows the termination of DNA synthesis, the post-synthetic phase. 
 
4. Mitosis ensures, the G2 cell, containing a double complement of DNA, divides in to 2 
daughter GI cells, may immediately re-enter to the cell cycle. 
 
 
Antitumor drugs are better at killing cells during DNA synthesis and active 
division. When a tumor is young, most of its cells are making DNA. This is defined as 
large growth function in this state, tumors are destroyed by drugs because the majority of 
their cells are making DNA and dividing. 
 
The major problems in cancer chemotherapy are the toxic drugs effects on 
normal cells and the rapid clearance of the drug from the tumor cells. Useful drugs 
without side effects do not at exist. Rapidly dividing normal cell such as hair follicles, 
cells lining the gastrointestinal tract and bone marrow cells involved in the immune 
defense system are also destroyed by the present day chemotherapy. Nausea, hair loss, 
increased susceptibility to infection and many others comprising a discouraging list. 
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Liposomes: An ideal “Drug Carrier” for anticancer drugs 
 
 
 
 
Anticancer drugs are known to produce serious side effects to other healthy 
 
tissues. The more serious effects are myocardiopathy and pulmonary toxicity. 
 
Therefore targeting such type drugs to the cancerous cell is essential 
 
because these drugs are new for the treatment of different type of carcinomas effectively. 
Usually a therapeutically profitable target agent relationship is far from ideal and 
undesirable side effects are usually observed. The alternative is to use simple functional 
molecules which transport the drug to the specific site and release it to perform task. 
Liposomes are non-toxic, biodegradable microcapsule made up of one or multiple lipid 
bilayers membranes 
 
 
Chemicals of interest can be entrapped inside the aqueous compartment of 
Liposomes or can be incorporated in to the lipid bilayer. Covalent attachment of 
functional group to lipid molecules adds flexibility to liposomes. Liposomes have been 
proved a suitable vehicle for selective drug delivery and controlled drug release. 
 
Important characteristics of drug carrier include protection of the encapsulated 
compound. Selective delivery of the entrapped material to specific tissues with minimal 
losses of drug during transit, regulation of the drug delivery rate, reduction of toxicity 
and removal of unused drug. All these function can co-exist in a single liposome 
preparation which makes it an ideal carrier of drug. Liposomes have proved to be 
suitable vehicles for antitumor dr 
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Figure No: 6 Accumulations of Liposome’s within Solid Tumors 
 
 
 
 
If liposomes carrying a drug are exposed to oxygen radicals, the hydro peroxides 
formed will affect the permeability, behavior of the vesicles, thus causing premature 
release of the drugs targeting to a specific site. The targeting of compounds attached to 
proteins of polymers, which may be modified by radical attack, could provoke an 
adverse response thus amplifying the initial damage. Eg: In microbial infections with 
excessive phagocyte action or in disease involving redistribution and de-
compartmentalization of iron. However optimization of a particular function is possible 
by modifying liposome composition, charge and size. 
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1.11 LYOPHILIZATION24 
 
Lyophilization is a process which extracts the water from foods and other 
products so that the foods or products remain stable and are easier to store at room 
temperature (ambient air temperature). Lyophilization is carried out using a simple 
principle of physics called sublimation. Sublimation is the transition of a substance from 
the solid to the vapour state, without first passing through an intermediate liquid phase. 
To extract water from foods, the process of lyophilization consists of: 
 
1. Freezing the food so that the water in the food becomes ice 
 
2. Under a vacuum, sublimating the ice directly into water vapour; 
 
3. Drawing off the water vapour; 
 
4. Once the ice is sublimated, the foods are freeze-dried and can be removed from 
the machine. 
 
Processing: 
 
The fundamental process steps are: 
 
 
 
 
1. Freezing: The product is frozen. This provides a necessary condition for low 
temperature drying. 
 
2. Vacuum: After freezing, the product is placed under vacuum. This enables the frozen 
solvent in the product to vaporize without passing through the liquid phase, a process 
known as sublimation. 
 
3. Heat: Heat is applied to the frozen product to accelerate sublimation. 
 
4. Condensation: Low-temperature condenser plates remove the vaporized solvent from 
the vacuum chamber by converting it back to a solid. This completes the separation 
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process. 
 
The first step in the lyophilization process is to freeze a product to solidify all of 
its water molecules. Once frozen, the product is placed in a vacuum and gradually heated 
without melting the product. This process, called sublimation, transforms the ice directly 
into water vapor, without first passing through the liquid state. The water vapor given off 
by the product in the sublimation phase condenses as ice on a collection trap, known as a 
condenser, within the lyophilizer's vacuum chamber. 
 
 
 
To be considered stable, a lyophilized product should contain 3% or less of its 
original moisture content and be properly sealed. 
 
 
 
Lyophilization Equipment : 
 
 
 
 
A lyophilizer consists of a vacuum chamber that contains product shelves 
capable of cooling and heating containers and their contents. A vacuum pump, a 
refrigeration unit, and associated controls are connected to the vacuum chamber. 
 
Chemicals are generally placed in containers such as glass vials that are placed 
on the shelves within the vacuum chamber. 
 
Cooling elements within the shelves freeze the product. Once the product is 
frozen, the vacuum pump evacuates the chamber and the product is heated. Heat is 
transferred by thermal conduction from the shelf, through the vial, and ultimately into 
the product. 
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Lyophilization Container Requirements: 
 
 
 
 
The container in which a substance is lyophilized must permit thermal 
conductivity, be capable of being tightly sealed at the end of the lyophilization cycle, 
and minimize the amount of moisture to permeate its walls and seal. The enclosed 
reagents can only remain properly lyophilized if the container in which they are 
processed meets these requirements. 
 
Advantages: 
 
 
 
 
Lyophilization has many advantages compared to other drying and preserving 
techniques. 
 
1. Lyophilization maintains food/ biochemical and chemical reagent quality because 
they remains at a temperature that is below the freezing-point during the process of 
sublimation; The use of lyophilization is particularly important when processing lactic 
bacteria, because these products are easily affected by heat. 
 
 
 
2. Food/biochemicals and chemical reagents which are lyophilized can usually be stored 
without refrigeration, which results in a significant reduction of storage and 
transportation costs. 
 
3. Lyophilization greatly reduces weight, and this makes the products easier to transport. 
For example, many foods contain as much as 90% water. These foods are 10 times 
lighter after lyophilization. 
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4. Because they are porous, most freeze-dried products can be easily rehydrated. 
Lyophilization does not significantly reduce volume; therefore water quickly regains its 
place in the molecular structure of the food/ bio chemicals and chemical reagents. 
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2. LITERATURE REVIEW 
 
 
 
Amarnath Sharma et al.,25 described that liposomes are micro 
particulate lipoidal vesicles which are under extensive investigation as drug 
carriers for improving the delivery of therapeutic agents. In this they have 
discussed the potential applications of liposomes in drug delivery with examples 
of formulation approved for clinical use, and the problems associated with 
further exploitation of these drug delivery systems. 
 
 
Antoneta et al.,26 studied effect of cholesterol and other sterols are 
important components of biological membranes and are known to strongly 
influence the physical characteristics of lipid bilayers. Although this has been 
studied extensively in fully hydrated membranes, little is known about the effects 
of cholesterol on the stability of membranes in the dry state. 
 
 
Chien et al.,27 have described the concept of designing specific delivery 
systems to achieve selective drug targeting. In this they compared between the 
conventional and targeted drug delivery systems. Also described 
principle,advantages and disadvantages of target drug delivery systems, and 
rationale of targeted drug delivery systems. 
 
 
Eugenia et al.,28 have reported the advantages and application of 
liposome with respect to anti-cancer, anti-inflammatory and anti-microbial 
agents. In this they described advantages of encapsulation of macromolecules 
like enzymes into liposomes. In this study they incorporated the enzymes into 
liposomes by dried film hydration method and studied the therapeutic activity of 
enzymes. 
 
 
Fresta et al.,29 have loaded of 5FU in liposomes by different methods and 
characterized encapsulation efficacy, storage stability and fusogenic properties. They 
concluded that the most suitable liposome preparation was the SPL that 
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showed both better drug loading and stability parameters than others. 
 
 
Ganesh et al.,30 have studied Inclusion of docetaxal in 
liposomal formulation. Studied the effect of drug antitumor activity. They have 
formulated docetaxal liposomes using Phosphatidyl choline (soybea lecithin), 
cholesterol and various stabilizers by dried thin film hydration method. They 
have evaluated Particle size analysis, drug content and entrapment efficiency in 
charged Liposomes were strongly affected by the different stabilizers, and 
stability of the lyophilized docetaxel Liposomes were evaluated after stored at 
40C and room temperature for 3 months. The Liposomes stored at 40C were 
found to be stable for duration of 3months. Hence it can be concluded that 
stabilizers like Stearylamine and Dicetylphosphate along with cholesterol were 
suitable carrier for the preparation of liposomal docetaxel. 
 
 
Gautam Vinod et al.,31 have developed a long circulating non-pegylated 
liposomes consisting of doxorubicin for parenteral administration. The 
circulation time in Swiss albino mice was measured for both formulations 
(conventional and non-pegylated). The non-pegylated liposomes are stable, 
exhibit low toxicity and have been found to be efficacious in different tumor 
models. 
 
 
Gregoiadis et al.,32 have developed liposomal formulation using (egg 
phosphatidly choline). In this they described usage of Triton-X 100 for finding 
out the percentage of drug loading in liposome. They found that Triton-X 100 
can be used to disrupt the lipid bilayer in liposome. 
 
 
Jain et al.,33 described the target drug delivery systems were likely to 
overcome much of the criticism of conventional dosage forms. They summarized 
that the optimized drug delivery that encompasses greater potency & 
effectiveness, lesser side effects and toxicity, better stability, low cost hence 
greater accessibility, ease of administration and best patient compliance. They 
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also described about carriers used in targeted drug delivery systems. 
 
 
Jian-chiou su et al.,34 have established a solid phase synthesis to prepare 
peptide-poly(ethylene glycol)-lipid(peptide-PEG-lipid) conjugates. In octreotide-
PEG2000-DSPE(OPD2000) used as model drug. The OPD2000 obtained had 
confirmed structure, activity, and purity providing a targeting molecule for 
preparation of well-defined drug delivery systems, such as targeted liposomes, 
for further studies. 
 
 
 
 
Lasic et al.,35 have described about the recent discoveries in the field 
 
of liposomes and latest application of liposomes. and explained the usage of 
different types of liposomes and their advantages. They also studied the efficacy 
of DNA encapsulation in liposomes. In the treatment of colon carcinoma and 
AIDS related Kaposi sarcoma. And they concluded that the liposomes can be 
used as carrier for biological like RNA, DNA, etc. 
 
 
 
 
Luigi Cattel et al.,36 have synthesized a series of increasingly lipophilic 
pro drugs of gemcitabine by linking the 4-amino group with valeroyl, heptanoyl, 
lauroyl and stearoyl linear acyl derivatives and studied their stability at storage, 
in plasma and with the lysosomal intracellular enzyme cathepsins. They also 
studied incorporation of these lipophilic prodrugs in liposomes, and concluded 
that encapsulation efficiency (EE) closely depends on the length of the saturated 
4-(N)-alee chain, the phospholipids chosen and the presence of cholesterol. 
 
 
             Marc Ostro et al.,37 have developed liposomal preparation of different 
drugs and evaluated in different disease states and they concluded that liposomes 
are better dosage form than conventional dosage forms. They have also stated the 
drug can be targeted by active and passive targeting mechanism using liposomes. 
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Sayed Daoud et al.,38 have described the challenge of chemotherapy in 
this they discussed about liposomes in cancer therapy and liposomes an ideal 
 
“drug carrier” for anti cancer drugs. They described the preclinical studies, 
clinical trials-phase 1 and 2 and drug resistance of anthracyclines and also 
described alkylating agents and platinum compounds. 
 
Sydney et al.,39 have described the cancer chemotherapy, in this they 
discussed incidence, geographic distribution and behavior of specific types of 
cancer. In that they described the mode of action, adverse effects, clinical use and 
dose administration of different chemotherapeutic agents. 
 
 
 
 
Tyrrell et al.,40 have described the general consideration and 
method of preparation of liposomes and also described about liposome-protein 
interaction and protein entrapment in liposomes. They summarized about uptake 
of liposomes in vivo and interaction of liposomes with cell culture and 
immunological aspects of liposomes. 
 
 
Wollina et al.,41 have studied the usage of two drugs namely, 
doxorubicin and daunorubicin in liposomal formulation for treatment of skin 
cancer like cutaneous T- cell lymphoma, malignant melanoma, AIDS related 
Kaposis sarcoma. They formulated liposomes with synthetic phospholipids and 
stabilizing agents like stearylamine and cholesterol. They also found that the 
efficacy of drug is improved in liposomal formulation than that of free drug. 
 
 
Xiaojuan Yang et al.,42 have described liposomes, comprising 
hydrogenated soy phosphatidylcholine (HSPC),cholesterol and poly (ethylene 
glycol) 2000-distearoyl phosphatidylethanolamine (PEG-DSPE), were preparedby 
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polycarbonate membrane extrusion and then loaded with flavopiridol by a pH-
gradient driven remote loading procedure. The liposomes had a mean diameter of 
120.7nm and a flavopiridol entrapment efficiency of 70.4%. 
 
. A. Laouini et al.,43 Liposomes, spherical-shaped nanovesicles, were discovered 
in the 60ies by Bangham. Since that,they were extensively studied as potential 
drug carrier. Due to their composition variability andstructural properties, 
liposomes are extremely versatile leading to a large number of applications 
including pharmaceutical, cosmetics and food industrial fields. This bibliographic 
paper offers a general review on the background and development of liposomes 
with a focus on preparation methods including classic (thin film hydration, 
reverse-phase evaporation, ethanol injection…) and novel scalable techniques. 
Furthermore, liposome characterization techniques including mean size, 
zetapotential, lamellarity, encapsulation efficiency, in vitro drug release, vesicles 
stability and lipid analysis synthesized from different published works are 
reported. 
 
 
 
Maharshi, et al.44 Repoted that Doxorubicin is an effective anticancer 
drug used in the treatment of several cancers such as osteosarcoma, kaposis 
sarcoma. The usage of the drug is limited because of its adverse effects on the 
heart. To reduce the adverse effects and to increase the release rate doxorubicin is 
formulated into liposomal dosage form. The liposomes are prepared by the thin 
film hydration method. Using soya lecithin as the phospholipid. This study mainly 
explains about the effect of concentration of soyalecithin, cholesterol and DSPE-
MPEG2000 on the particle size of formulated liposomes which ranges in between 
 
0.766 ± 0.03μm to 13.56 ± 0.10 μm drug entrapment efficiency of different 
formulations in which maximum entrapment efficiency was determined as 96.45 
 
± 0.95 % and minimum was 24.89 ± 1.18 % , zeta potential which is determined 
as -0.271 mV, in vitro drug release in which the the maximum sustain release was 
found as 41.45 ± 1.06 % and stability studies at different temperatures and 
maximum drug retention was found in refrigerated temperature 2-8 oC. 
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Arvind, et al. 46 Amphotericin B is a polyene antifungal drug used 
intravenously for systemic fungal infections. Liposomal formulation of 
amphotericin B for injection, prepared by thin film hydration technique was 
selected in the present study. Different formulations variables (solvents ratio and 
pH of complex formation) and process variable (numbers of homogenization 
cycles) were carried out to control the impurities levels and particle size of 
liposomes. Formulation prepared at pH 3.0 with 1:2 solvent ratio (Methanol: 
Chloroform) was given least impurities. Formulation prepared at 1400 bar 
pressure with 15 homogenization cycles was shown desire particle size. The 
optimized formulation was exhibited more than 90% release of drug for a period 
of 7 days. The stability study (40±2°C/ 75±5% RH) of the Amphotericin B 
liposomes was evaluated for 3 months and it was found to be stable. 
 
A.D. Carvalho Júnior47, Encapsulated cisplatin into stealth pH-sensitive 
liposomes and studied their stability, cytotoxicity and accumulation in a human 
small-cell lung carcinoma cell line (GLC4) and its resistant 
subline(GLC4/CDDP). Since reduced cellular drug accumulation has been shown 
to be the main mechanism responsible for resistance in theGLC4/CDDP sub line, 
we evaluated the ability of this new delivery system to improve cellular uptake. 
The liposomes were composed of dioleoyl phosphatidyl ethanolamine (DOPE), 
cholesteryl hemisuccinate(CHEMS), and distearoylphosphatidylethanolamine-
polyethyleneglycol2000 (DSPE-PEG2000) and were characterized by 
determining the encapsulation percentage as a function of lipid concentration. 
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3. DRUG AND EXCIPIENTS PROFILE 
 
 
 
 
3.1 DRUG PROFILE 
 
Cisplatin: 
 
Cisplatin,  is  an  anticancer  drug,  belongs  to  alkylating  agents  class. 
 
Cisplatin is commonly used for the treatment of a wide range of cancers, majorly 
used to testicular and ovarian cancers and s a r c o m a s many types of 
carcinoms. 
 
Chemistry49: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(STRUCTURE OF CISPLATIN) 
 
 
 
 
Iupac Name (SP-4-2)-diammine dichloridoplatinum 
 
Molecular formula: H6Cl2N2Pt 
 
Molecular weight: 301.1gm/mol. 
 
Melting point: 270-300
o
 C. 
 
Physical description: Yellow powder or Orange yellow crystals. 
 
Solubility: Sparingly soluble in dimethylformamide, slightly soluble in water and 
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practically Insoluble in ethanol (95%). 
 
Bioavailability: 95%. 
 
Half-life:20-30 min. 
 
Mechanism of action50: 
 
Alkylating agents work by three different mechanisms: 1) attachment of 
alkyl groups to DNA bases, resulting in the DNA being fragmented by repair 
enzymes in their attempts to replace the alkylated bases, preventing DNA 
synthesis and RNA transcription from the affected DNA, 2) DNA damage via the 
formation of cross-links (bonds between atoms in the DNA) which prevents DNA 
from being separated for synthesis or transcription, and 3) the induction of 
mispairing of the nucleotides leading to mutations. 
 
Pharmacokinetics50: 
 
After intravenous administration Cisplatin disappears from the plasma in 
a biphasic manner and half-lives of 25 to 49 minutes and 58 to 73 hrs have been 
reported for total platinum. 
 
The majority of the platinum from a dose is rapidly bound to plasma 
protein. Cisplatin is concentrated in liver, kidney, and large and small intestines. 
Penetration into the CNS appears to be poor. Excretion is mainly in the urine but 
is incomplete and prolonged, up to about 50% of a dose has been reported to be 
excreted in urine over 5 days and platinum may be detected in tissues for several 
months afterwards. Cisplatin is well absorbed following intra peritoneal 
administration 
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Pharmacodynamics: 
 
Cisplatin is an antineoplastic in the class of alkylating agents and is used 
to treat various forms of cancer. Alkylating agents are so named because of their 
ability to add alkyl groups to many electronegative groups under conditions 
present in cells. They stop tumor growth by cross-linking guanine bases in DNA 
double-helix strands - directly attacking DNA. This makes the strands unable to 
uncoil and separate. 
 
As this is necessary in DNA replication, the cells can no longer divide. In 
addition, these drugs add methyl or other alkyl groups onto molecules where they 
do not belong which in turn inhibits their correct utilization by base pairing and 
causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. 
Alkylating agents work by three different mechanisms all of which achieve the 
same end result - disruption of DNA function and cell death 
 
The following adverse reactions are discussed in more detail in other sections of 
the labeling. 
 
 
Neuro toxicity 
 
Ototoxicity 
 
The most common adverse reactions observed with Cisplatin 
 
Fatigue 
 
Fever 
 
ausea 
 
Stomatitis 
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ting 
arrhea 
 
 
rexia 
 
ash and Neutropenia 
rombocytopenia and anemia 
 
 
 
3.2 LIPID PROFILE: 
 
 
 
 
3.2.1 Cholesterol: 
 
Cholesterol is a waxy steroid of fat that is manufactured in the liver or 
intestines. It is used to produce hormones and cell membranes and is transported 
in the blood plasma of all mammals. It is an essential structural component of 
mammalian cell membranes. It is required to establish proper membrane 
permeability and fluidity. In addition cholesterol is an important component for 
the manufacture of bile acids, steroid hormones and vitamin D. 
 
 
Description: 
 
White or faintly yellow, almost odorless, pearly leaflets, needles, powder 
and granules. On prolonged exposure to light and air cholesterol acquires a 
yellow to tan color. 
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CHEMISTRY49: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(STRUCTURE OF CHOLESTEROL) 
 
 
 
IUPAC name : (3β)-Cholest-5-en-3-ol 
 
Synonyms: Cholestrin 
 
Molecular Formula: C27H46O 
 
Molar mass:  386.65 g/mol 
 
Appearance: white 
crystalline powder 
 
Density: 1.052 g/c 
 
Melting point: 148-150
o
C 
 
Boiling point: 360
o
C (decomposes) 
 
Solubility in water: 0.095 mg/L (30
o
C) 
 
Solubility: Soluble in acetone, benzene, chloroform, ethanol, ether, 
hexane, isopropyl myristate and methanol. 
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Cholesterol is oxidized by the liver in to a variety of bile acids. These in 
turn are conjugated with glycine, taurine, glucuronic acid, or sulphate. A mixture 
of conjugated and non-conjugated bile acids along with cholesterol itself is 
excreted from the liver in to the bile. 
 
Approximately 95% of the bile acids are reabsorbed from the intestine 
and the remainder lost in the feces. The excretion and re-absorption of bile acids 
forms the basis of the entero-hepatic circulation which is essential for the 
digestion and the absorption of dietary fats. Under certain circumstances, when 
more concentrated, as in the gallbladder, cholesterol crystallizes and is the major 
constituent of most gallstones, although lecithin and bilirubin gallstones also 
occur less frequently. 
 
Cholesterol is required to build and maintain cell membranes it regulates 
membrane fluidity over a wide range of temperatures. The liver produces about 1 
gram of cholesterol per day, in bile. The hydroxyl group on cholesterol interacts 
with the polar. Head groups of the membrane phospholipids and Sphingolipids, 
while the bulky steroid and the hydrocarbon chain is embedded in the membrane, 
alongside the non-polar fatty acid chains of the other lipids. Bile which is stored 
in the gallbladder and helps digest fats is important for the absorption of the fat 
soluble vitamins, vitamins A, D, E and K. It also reduces the permeability of the 
plasma membrane. In myelin, it envelops and insulates nerves, helping greatly to 
conduct nerve impulses. It also reduces the permeability of the plasma membrane 
to protons (Positive hydrogen ions) and sodium ions. 
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Stability and storage Condition 
 
Cholesterol is stable and should be stored in a well closed container, 
protected from light. 
 
 
3.2.2 Hydrogenated Soya phosphatidyl Choline 
 
Phospholipid molecule generally consists of hydrophobic tails and a 
hydrophilic head. Biological membranes in eukaryotes also contain another class 
of lipid, sterol, interspersed among the phospholipids and together they provide 
membrane fluidity and mechanical strength. Purified phospholipids are produced 
commercially and have found applications in nanotechnology and materials 
science. 
 
Chemistry49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synonyms50: Hydro Soy PC. 
 
Molecular Formula: C27H46O. 
 
Molar mass:  783.774gm/mol. 
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Appearance: white powder. 
 
Boiling point: 50-60 
o
C 
 
Solubility in water: insoluble in water. 
 
Solubility: Soluble in acetone, benzene, insoluble in 
triglycerides,alcohol and water. 
 
Storage: Keep container tightly closed in a dry and well-ventilated place. 
 
 
 
 
 
3.2.3 Mpeg-dspe ( Methoxyl polyethylene glycol DSPE ) 
 
 
Description 
 
 
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine(DSPE) conjugated 
Polyethylene Glycol, DSPE PEG is a phospholipid PEG conjugate which has both 
hydrophilicity and hydrophobility. Pegylated phospholipids are excellent 
liposome formation materials that can be used for drug delivery, gene transfection 
and vaccine delivery as well. Pegylation of phospholipids significantly improves 
the blood circulation time and stability for encapsulated drugs. These materials 
can also be used for targeted drug delivery by modifying their surfaces with 
targeting ligands such as antibodies, peptides. 
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Chemistry49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(STRUCTURE OF Mpeg-dspe) 
 
 
Physical Properties50: 
 
 
• Off-white/white solid or viscous liquid depends on molecule 
weight 
 
• Soluble in regular aqeous solution as well as most organic solvents 
 
 
Storage : 
 
 
Store at -20 0C, desiccated Protect from light, Avoid frequent thaw and 
 
freeze 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dept. of Pharmaceutics,                                                                     JKKMMRF College of pharmacy 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM & PLAN OF WORK 
Chapter No: 4 Aim & Plan of Work 
 
 
4. AIM OF THE WORK 
 
 
The aim of the present study was to 
 
9 Compatibility study of API with lipids & cholesterol.  
9 Development of liposomal formulation.  
9 In-vitro characterization of liposomal formulation.  
9 Selection of best formulation based on the In-vitro characterization data.  
9 Lyophilization of the best formulation. 
 
Scope of the study 
 
Cisplatin, an anticancer drug, belongs to alkylating agents class. Though it has great 
importance in treating the cancers, its importance is decreasing due to its high protein 
binding character (which decreases bioavailability). 
 
Recent literature is substantiating that Liposomal technology is one of the 
prominent technology for targeting drug delivery. Also stating that, by means of this 
technology one can increase the safety, efficacy of the drug molecules, achieves better 
compliance, bioavailability, etc. 
 
Hence an attempt has-been made to avoid the protein binding of cisplatin by 
decreasing the exposure of the drug to proteins by enclosing the drug in liposomes. 
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PLAN OF WORK 
 
STAGE 1: 
 
1. Preformulation studies 
 
a. Standard calibration curve of Cisplatin in UV 
 
b. Compatibility studies 
 
 
 
 
STAGE 2: 
 
1. Preparation of Plain Liposomes with Ammonium sulphate and stabilizers. 
 
2. Preparation of drug loaded liposomes with Stabilizers by Dried Thin Film 
Hydration Technique. 
 
 
STAGE 3: 
 
1. Physical characterization of liposomes 
 
a. Particle size analysis 
 
b. Zeta potential 
 
c. Transmission electron microscopy 
 
d. Scanning electron microscopy 
 
e. Polydispersity index 
 
 
 
 
STAGE 4: 
 
1. In- vitro charactarization 
 
a. Encapsulation efficiency 
 
b. Assay 
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c. Study on in-vitro drug release 
 
d. Release kinetics 
 
STAGE 5: 
 
1. Short term stability studies 
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5. MATERIALS & METHODS 
 
 
 
 
5.1 LIST OF CHEMICALS 
 
Table No: 3 List of Chemicals used for the work 
 
 
S.No Ingredients Manufactures 
   
1 Cisplatin Nicholas and Piramal.Indore.Cipla 
.  Bangalore.
  
2 Hspc Lipoid Pvt. Ltd., Mumbai. 
.   
   
3 Cholesterol Lipoid Pvt. Ltd., Mumbai. 
.   
   
4 Mpeg –dspe Sigma Aldrich, Mumbai. 
.   
5 Ammonium sulphate Triveni chemicals, Mumbai. 
.   
   
6 Sucrose Triveni chemicals, Mumbai. 
.   
7 Histidine Merck chemicals, Mumbai. 
.   
   
8 Chloroform Fisher scientific, Mumbai. 
.  . 
9. Sodium hydroxide Merck chemicals, Mumbai. 
   
10. Triton X-100 Merck chemicals, Mumbai. 
   
11. Acetonitrile Merck chemicals, Mumbai. 
   
12. Methanol Merck chemicals, Mumbai. 
   
13. Sodium lauryl sulphate Merck chemicals, Mumbai. 
   
14. Isopropyl alcohol Merck chemicals, Mumbai. 
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5.2 LIST OF EQUIPMENTS 
 
 
Table No: 4 List of Equipment used in the work 
 
S.No Equipment Manufacturer 
   
1. UV- Visible spectrophotometer PerkinElmers
   
2. Infra Red spectroscopy Bruker
   
3. Rotary vacuum evaporator Buchi
   
4. Homogenizer Panda
   
5. Peristaltic pump Electro lab
   
6. Electronic balance Sartorius
   
7. Centrifuge Remi Instruments
   
8. Bath Sonicator Jeken Ultrasonic
   
9. Electronic Microscope Motic
   
10. HPLC LC20AD, Shimadzu 
   
11. Magnetic stirrer Remi Instruments
   
12. Zeta Sizer version 6.00 Malvern
   
13. Scanning Electron Microscopy Field Instruments
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dept. of Pharmaceutics,       JKKMMRF College of pharmacy  
56 
Chapter No: 5 Materials & Methods 
 
 
 
 
 
5.3 STANDARD CALIBRATION CURVE 
 
 
Standard calibration curve of Cisplatin was developed in phosphate buffer pH 7.4 
and estimated by UV-Visible spectrophotometer at 301nm. 
 
 
5.3.1 General Procedure for the preparation of calibration curve by UV 
 
 
A stock solution of (1mg/ml) of standard drug was prepared, later required 
dilutions were made with a phosphate buffer pH 7.4. From the stock solution a serial 
dilutions made to obtain the re write solutions having concentration 10 –80 µg/ml, using 
phosphate buffer pH 7.4 as makeup solution, the absorbance were recorded at 301nm 
using UV- Visible spectrophotometer. Absorbance values were plotted against respective 
concentration to obtain standard calibration curve. 
 
 
5.3.2 Preparation of Phosphate Buffer pH 7.4 
 
 
Take accurately 1.564 gm of sodium hydroxide and 6.804gm potassium 
dihydrogen phosphate and dissolved in small volume of distilled water and made volume 
up to 1000 ml. The resulting solution is phosphate buffer having pH 7.4. 
 
 
5.4 COMPATIBILITY STUDIES 
 
5.4.1 FT-IR 
 
IR spectroscopy was used to investigate and predict any physicochemical 
interactions between API and excipients in a formulation. Based on the results suitable 
chemically compatible excipients were chosen. 
 
 
The following compounds IR spectroscopy were recorded 
 
 
 
Hydroxy soya phosphatidyl choline 
rol 
 
–Dspe 
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of Hspc and drug 
 
of cholesterol, and drug 
of mpeg-Dspg and drug 
 
One part of the sample and three parts of potassium bromide were taken in a 
mortar and triturated. A small amount of triturated sample was taken in to a pellet maker 
and was compressed at 10kg/cm2 using hydraulic press. The pellet was kept on to the 
sample holder and scanned from 4000cm-1to 400cm-1 in Bruker IR spectrophotometer. 
Then it was compared with original spectra. 
 
 
IR spectra was compared and checked for any shifting in functional peaks and 
non-involvement of functional group. From the spectra it is clear that there is no 
interaction between the selected carriers, drug and mixtures. Hence the selected carrier 
was found to be compatible in entrapping the selected cisplatin with carriers without any 
mutual interactions. 
 
 
5.5 PREPARATION OF CISPLATIN LIPOSOMES 
 
 
5.5.1 Procedure for the preparation of Cisplatin liposome 
 
Liposomes were prepared using soya phosphatidyl choline (HSPC) by dried thin 
film hydration technique using rotary evaporator. 
 
Accurately weighed quantities of Hspc, cholesterol, Mpeg-dspe and are dissolved 
in chloroform and methanol rotated in a rota-evaparator by applying vaccum of about 
25mmHg at 250c, until it forms a thin film. Required quantities of ammonium sulphate 
and sucrose (0.3%) are dissolved in W.F.I and it is added to the above thin film in R.B 
flask and rotated until it forms a milky white suspension. The above solution is 
homogenized for 15 cycles to reduce particle size of liposomes. 
 
 
The above solution is undergone for 25 cycles of dialysis, by using sucrose 
solution (10%) to remove free ammonia and sulphate from the lipid solution. 
 
Drug solution is prepared by adding the required quantities of Drug and Tocoferol 
in a W.F.I and drug solution is added to the solution in a R.B flask (lipid solution) and 
rotated for 1hr. 
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Table No: 4 The composition of Drug, Soy Hspc, Cholesterol, Mpeg-dspe, 
Tocoferol and Ammonium sulphate. 
 
Formul Drug Hspc Cholesterol Mpeg-dspe tocoferol Ammonium,
ation (cispl (gm/10   (ml/100ml Sulphate atin) (gm/100ml) (gm/100ml   
code  0ml)  ) ) (gm/100ml)
       
F1  3.5 1.75 1.5 0.1 3.96
       
F2 40mg/ 3.85 1.75 1.5 0.1 3.96      
 
15ml 
     
F3 4.0 2.0 1.85 0.1 3.96
 
       
F4  4.25 2.0 1.85 0.1 3.96
       
F5  4.25 2.25 2.0 0.1 3.96
       
F6  4.5 2.5 2.0 0.1 3.96
       
 
 
 
5.6 CHARACTERIZATION OF LIPOSOMES 
 
 
All the liposomal formulation was evaluated for physicochemical properties like 
 
Particle size analysis  
Polydispersity index  
Zeta potential analysis  
SEM analysis ¾ TEM  
¾ Determination of free drug  
¾ Assay  
¾ Invitro drug release  
¾ Stability studies  
 
5.6.1 Determination of particle size distribution 
 
Determination of average vesicle size of liposomes was very important. Hence it was 
carried out by using MALVERN INSTRUMENT in JAWAHARLAL NEHRU 
TECHNOLOGICAL UNIVERSITY. 
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5.6.2 Polydispersity Index: 
 
Polydispersity was determined according to the equation, 
 
 
Polydispersity = D (0.9) - D (0.1) / D (0.5) 
 
Where, 
 
D (0.9) corresponds to particle size immediately above 90% of the sample. 
D (0.5) corresponds to particle size immediately above 50% of the sample. 
D (0.1) corresponds to particle size immediately above 10% of the sample. 
 
5.6.3 ZETA POTENTIAL ANALYSIS 
 
 
Zeta potential is a physical property which is exhibited by any particle in suspension. 
It can be used to optimize the formulations of suspensions and emulsions. It is an aid in 
predicting long-term stability. The magnitude of the zeta potential gives an indication of 
the potential stability of the colloidal system. If all the particles in suspension have a large 
negative or positive zeta potential then they will tend to repeal each other and there will be 
no tendency for the particles to come together. However, if the particles have low zeta 
potential values then there will be no force to prevent the particles coming together and 
flocculating. 
 
A value of 25mV (positive or negative) can be taken as the arbitrary value that 
separates low-charged surfaces from high-charged surfaces. 
 
The  zeta  potential was analyzed by MALVERN ZETASIZER in JAWAHARLAL 
 
NEHRU TECHNOLOGICAL UNIVERSITY. 
 
 
5.6.4 TRANSMISSION ELECTRON MICROSCOPY 
 
 
 
TEM (Hitachi, H-7500, Germany) was a method of probing the microstructure of 
rather delicate systems such as micells, liquid crystalline phases, vesicles and emulsions. 
The shape and size of optimized liposomal formulation is observed by TEM investigation. 
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               5.6.5 SCANNING ELECTRON MICROSCOPY             
 
Determination of surface morphology (roundness, smoothness and formation of 
aggregates) of cisplatin Liposomes was carried out by scanning electron microscopy 
(SEM). 
 
The Scanning Electron Microscopy (SEM) was analyzed by FIELD INSTRUMENT 
in OSMANIA UNIVERSITY 
 
5.7 IN-VITRO CHARACTERIZATION 
 
 
5.7.1 Determination of free drug by Triton-X100 method 
 
Take 1ml of liposomal solution in 10ml volumetric flask and make it up to the mark 
with 5%sucrose and determine the absorbance. Since the absorbance value is above 1 for 
10 dilituion sample , 1ml from the dilution sample is take and made upto the mark with 5% 
sucrose and determine with uv-visible spectrophotometer. From the absorbance, determine 
the concentration of the free drug in liposomal solution. 
 
Again take 1 ml of liposomal sample and add 1ml of triton- x100 and make it with 5% 
sucrose solution in a 10ml volumetric flask. From the absorbance amount of free drug in 
liposomal sample is determined. 
 
5.8 Cisplatin Assay 
 
A standard and sample solution were prepared, Inject separately 20 microlitre of 
the standard and sample solution in chromatographic condition and record the 
chromatogram. Calculate the content of drug per ml in liposomal injection as follows. 
 
 
Assay= A/B×W/200×5/50×C/100×100-D/100×50/5×100/5 
 
Where, 
 
A = Area corresponding to Cisplatin in sample. 
 
B = Area corresponding to Cisplatin in working standard. 
 
C = % purity of Cisplatin in working standard. 
 
D = % water content of working standard 
 
. W = Weight of working standard in mg. 
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Chromatographic conditions: 
 
Column : C18 BDS (250×4.6mm) 
Mobile phase : Buffer + Acetonitrile + Methanol (47ml+48ml+ 5ml)
Buffer : 2.8% w/w sodium lauryl sulphate + 2.3% w/v 
  Phosphoric Acid. 
Wave length : 301nm. 
Flow rate : 1.7 sml/mn. 
Solvent : Acidified IPA (90mlIPA+ 0.68ml Hcl+ Make up to 
  100mlwith(water) 
 
5.9 In vitro diffusion studies of Cisplatin liposome 
 
 
The in vitro release studies of all liposomal suspension were performed using 
exhaustive dialysis method. Two side open ended glass tube was taken and one side has 
been closed with semi permeable membrane. The fabricated tube was used as donor 
compartment in which 2 ml of liposomal suspension was taken and placed in receptor 
compartment containing 200 ml phosphate buffer (PBS, Ph 7.4) with acetonitrile. The 
dialysis was carried out at 50 rpm at 37o C and stirred with the help of a magnetic stirrer. 
Aliquots (4ml) of release medium was withdrawn at different time intervals and the same 
volume was replaced with fresh phosphate buffer pH 7.4, to maintain sink condition 
volume and then the samples were analyzed by UV-Visible spectrophotometry at a λ max 
of 301nm. 
 
5.10. Release kinetics 
 
The release data fitted in various release kinetic models to know the mechanism of 
 
drug release kinetics. The zero order rate describes the systems where the  drug  release 
 
rate  is independent of  its concentration.  The  first order rate  describes the  release  from 
 
system where release rate is  concentration  dependent. Higuchi described the release of 
 
drugs from insoluble matrix as a square root of time dependent process based on fickian  
 
diffusion 
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Various release models 
 
1. Zero - order kinetic model – Cumulative % drug released versus time. 
 
2. First – order kinetic model – Log cumulative percent drug 
remaining versus time. 
 
3. Higuchis model – Cumulative percent drug released versus 
square root of time. 
 
4. Korsmeyer equation / Peppas model – Log cumulative percent 
drug released versus log time. 
 
a. Zero order kinetics: 
 
Zero order release would be predicted by the following 
equation: At = A0 – K0t 
Where 
 
At = Drug release at time„t 
 
A0 = Initial drug concentration. 
 
K0 = Zero- order rate constant (hr
-1
) 
 
 
 
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero – order kinetics and its slope is equal to Zero order release 
constant K0. 
 
 
 
b. First order kinetics: 
 
First - order release could be predicted by the following equation: 
 
 
 
 
Log C = log C0 – Kt / 
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2.303 
 
Where, 
 
C = Amount of drug remained at time„t 
 
C0 = Initial amount of drug. 
 
K = First - order rate constant (hr
-1
). 
 
 
 
When the data plotted as log cumulative percent drug remaining versus time, yields a 
straight line, indicating that the release follow first order kinetics. The constant 
 
„K1 can be obtained by multiplying 2.303 with the slope value. 
 
 
 
 
c. Higuchi’s model: 
 
Drug release from the matrix devices by diffusion has been described by following 
 
 
 
Higuchis classical diffusion equation: Q = [DЄ / τ(2A – ЄCs ) Cst]
1/2 
 
Where, 
 
Q = Amount of drug release at 
time„t 
 
D = Diffusion coefficient of the drug in the 
matrix. A = Total amount of drug in unit volume 
of matrix. Cs = Solubility of drug in the matrix. 
 
Є = Porosity of the 
matrix. τ = Tortuosity. 
 
t = Time (hrs at which q amount of drug is released. 
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Above equation can be simplified as if we assumes that „D, „Cs and „A 
are constant. Then equation becomes: 
 
Q = Kt
1/2 
 
5.10. Release kinetics 
 
The release data fitted in various release kinetic models to know the mechanism of 
drug release kinetics. The zero order rate describes the systems where the drug release rate 
is independent of its concentration. The first order rate describes the release from system 
where release rate is concentration dependent. Higuchi described the release of drugs from 
insoluble matrix as a square root of time dependent process based on fickian diffusion. 
 
 
Various release models 
 
1. Zero - order kinetic model – Cumulative % drug released versus time. 
 
2. First – order kinetic model – Log cumulative percent drug 
remaining versus time. 
 
3. Higuchis model – Cumulative percent drug released versus 
square root of time. 
 
4. Korsmeyer equation / Peppas model – Log cumulative percent 
drug released versus log time. 
 
a. Zero order kinetics: 
 
Zero order release would be predicted by the following 
equation: At = A0 – K0t 
Where 
 
At = Drug release at time„t 
 
A0 = Initial drug concentration. 
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K0 = Zero- order rate constant (hr
-1
) 
 
 
 
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero – order kinetics and its slope is equal to Zero order release 
constant K0. 
 
 
 
b. First order kinetics: 
 
First - order release could be predicted by the following equation: 
 
 
 
 
Log C = log C0 – Kt / 
2.303 
Where, 
 
C = Amount of drug remained at time„t 
 
C0 = Initial amount of drug. 
 
K = First - order rate constant (hr
-1
). 
 
 
 
When the data plotted as log cumulative percent drug remaining versus time, yields a 
straight line, indicating that the release follow first order kinetics. The constant 
 
„K1 can be obtained by multiplying 2.303 with the slope value. 
 
 
 
 
c. Higuchi’s model: 
 
Drug release from the matrix devices by diffusion has been described by following 
 
 
 
Higuchis classical diffusion equation: Q = [DЄ / τ(2A – ЄCs ) Cst]
1/2 
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Where,  
 Q  =  Amount  of  drug  release  at 
 time„t 
 D  =  Diffusion  coefficient  of  the  drug  in  the 
 matrix. A = Total amount of drug in unit volume 
 of matrix. Cs = Solubility of drug in the matrix. 
 Є = Porosity of the 
 matrix. τ = Tortuosity. 
 t = Time (hrs at which q amount of drug is released. 
 
 
 
 
 
 
 
Above equation can be simplified as if we assumes that „D, „Cs and „A are constant. 
 
Then equation becomes: 
 
Q = Kt
1/2 
 
 
 
 
When the data is splitted according to equation i.e. cumulative drug release versus square 
root of time yields a straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to „K (Higuchis 1963). 
 
 
 
d. Korsmeyer equation / Peppa’s model: 
 
To study the mechanism of drug release from the liposomal solution, the release data was 
also fitted to the well-known exponential equation (Korsmeyer equation/ Peppas law 
equation), which is often used to describe the drug release behavior from polymeric 
systems. 
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Mt / Mα = Kt
n 
 
Where, 
 
Mt / Mα = The fraction of drug released at time„t. 
 
 
 
 
K= Constant incorporating the structural and geometrical 
 
characteristics of the drug / polymer system. 
 
n = Diffusion exponent related to the mechanism of the release. 
 
 
 
 
Above equation can be simplified as follows by applying log on 
both sides, Log Mt / Mα = Log K+ n Log t 
 
 
 
 
 
5.11 Lyophilization 
 
Processing: 
 
The fundamental process steps are: 
 
1. Freezing: The product is frozen. This provides a necessary condition for low 
temperature drying 
 
2. Vacuum: After freezing, the product is placed under vacuum. This enables the 
frozen solvent in the product to vaporize without passing through the liquid phase, a 
process known as sublimation. 
 
3. Heat: Heat is applied to the frozen product to accelerate sublimation. 
 
4. Condensation: Low-temperature condenser plates remove the vaporized solvent 
from the vacuum chamber by converting it back to a solid. This completes the 
separation process. 
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Wet samples can be frozen by placing them in a vacuum. The more energetic 
molecules escape, and the temperature of the sample falls by evaporative cooling. 
Eventually it freezes. About 15% of the water in the wet material is lost. 
 
 
 
The simplest form of lyophilizer would consist of a vacuum chamber into which wet 
sample material could be placed, together with a means of removing water vapor so as to 
freeze the sample by evaporative cooling and freezing and then maintain the water-vapor 
pressure below the triple-point pressure. The temperature of the sample would then 
continue to fall below the freezing point and sublimation would slow down until the rate of 
heat gain in the sample by conduction, convection, and radiation was equal to the rate of 
heat loss as the more energetic molecules sublimed away were removed. 
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6 .RESULTS 
 
 
 
 
 
6.1: CALIBRATION CURVE OF CISPLATIN 
 
 
Table No 7: Standard Readings of Cisplatin in phosphate buffer pH 7.4 
 
 
S. No. Concentration Absorbance at 301nm 
   
1. 0 0
   
2. 10 0.101 
   
3. 20 0.224 
   
4. 30 0.311 
   
5. 40 0.425 
   
6. 50 0.540 
   
7. 60 0.645 
   
 80 0.830 
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Figure no:7 Standard graph of Cisplatin in phosphate buffer pH 7.4 
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DISCUSSION 
 
The UV absorbance of Cisplatin standard solution in the range of 10-80 µg/ml of 
drug in phosphate buffer pH 7.4 showed linearity at λ max 301nm. The linearity was 
plotted for absorbance against concentration with R2 value 0.9989 and with the slope 
equation y = 0.0106x + 0.0015. 
 
 
6.2: PREFORMULATION STUDIES OF CISPLATIN 
6.2.1: FT-IR STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 8 FTIR of cisplatin drug 
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Figure No: 9 FTIR of drug and Hspc.(1:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 10 FTIR of drug and Hspc.(1:5). 
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Figure No: 11 FTIR of Cisplatin and Hspc (5:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No : 12 FTIR of Cisplatin and Hspc (1:1) 
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Figure No: 13 FTIR of Cisplatin and cholesterol (1:5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 14 FTIR of Cisplatin and mpeg-dspe (5:1) 
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Figure No: 15 FTIR of Cisplatin and mpeg-dspe (1:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 16 FTIR of Cisplatin and mpeg-dspe (1:5) 
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Figure No: 17 FTIR of Cisplatin and mpeg-dspe (1:5) 
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Table no 8: Percentage correlations of drug and lipid mixtures 
     
   Percentage  
 S.no Formulation code compatibility ratio of  
   drug and excipients  
     
 1 Drug and Hspc.(1:1) 94.47  
     
 2 Drug and Hspc.(1:5) 91.89  
     
 3 Drug and Hspc.(5:1) 98.64  
     
 4 Drug and cholesterol (1:1) 93.08  
     
 5 Drug and Cholesterol (1:5) 91.60 
     
 6 Drug and cholesterol (5:1) 96.33  
     
 7 Drug and mpeg-dspe (1:1) 88.26  
     
 8 Drug and mpeg-dspe (1:5) 87.14  
     
 9 Drug and mpeg-dspe (5:1) 98.50 
     
 
 
DISCUSSION 
 
 
 
 
The compatibility between the drug and the selected lipid and other excipients 
was evaluated using FTIR peak matching method. The percentage correlations were 
evaluated and the results showing that there was no appearance or disappearance of 
peaks in the drug-lipid mixture, which confirmed the absence of any chemical 
interaction between the drug, lipid and other chemicals. 
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6.3 DIFFERENTIAL SCANNING CALORIMETRY (DSC) RESULTS 
 
 
 
 
DSC Ch1 Drug alone 12-51 2013-04-18.ta  DSC   
mW     
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Figure No: 18 D.S.C of Cisplatin drug 
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Figure No: 19 D.S.C: Cisplatin, Hspc, Mpeg-dspe and Cholesterol 
 
 
 
 
DISCUSSION 
 
 
 
 
The DSC curve of pure drug Cisplatin exhibits a sharp endothermic peak at 
320.1°C.The thermogram of drug-lipid mixture displayed endothermic peaks at 32.1°C, 
120.0°C,400.5°C. DSC measurements showed that drug-lipid mixture was having less 
ordered arrangement of crystals, and this was favorable for increasing the drug loading 
capacity. 
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6.4 DETERMINATION OF PARTICLESIZE DISTRIBUTION AND 
 
POLYDISPERSITY INDEX: 
 
Table no 9: particle size determination 
 
 
 
 
S.No Formulation Average Poly dispersive index (pdi) 
 code vesicular  
  size(nm)  
    
1 F2 289.2 0.247 
    
2 F6 108 0.461 
    
 
 
 
 
 
DISCUSSION 
 
 
 
 
The Liposomes were prepared by dried thin film hydration technique using 
rotary evaporator with drug and carrier (hydrogenated soya phosphatidyl choline).The 
formulation containing Cisplatin were prepared with stabilizer like tocoferol and all 
other parameters like temperature, vacuum and RPM were kept constant. The particle 
size distribution was analyzed for F2, F6 formulations of Cisplatin Liposomes by wet 
method. The particle size was optimum in F6 Formulation. Results were shown in figure 
no.20, 21. 
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Figure No: 20 Particle size distribution of F2 liposomal formulation. 
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Figure No: 21 Particle size distribution of Cisplatin F6 liposomal formulation 
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6.5 ZETA POTENTIAL ANALYSIS 
 
 
 
 
TableNo:10 Zeta potential values of Cisplatin Liposomes for Optimized Batch. 
 
S.No Formulation Code Zeta Potential(mV) 
   
1 F2 -17.0 
   
2 F6 -20.0 
   
 
 
 
 
 
DISCUSSION 
 
The zeta potential of the optimized formulation (F6) was found to be -20mV.Zeta 
potential is an important parameter that influences stability. Extremely positive or 
negative zeta potential values cause larger repulsive forces, whereas repulsion between 
particles with similar electric charge prevents aggregation of the particles and thus 
ensures easy redispersion. In case of a combined electrostatic and steric stabilization, a 
minimum zeta potential of ± 20 mV is desirable. The report was shown in fig.no.22,23. 
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Figure No: 22 Zeta potential for Cisplatin Liposomal F2 formulation 
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Figure No: 23 Zeta potential for Cisplatin Liposomal F6 formulation 
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6.6 TRANSMISSION ELECTRON MICROSCOPY (TEM): 
 
 
The  morphology  of  optimized  formulation  (F6)  produced  was  assessed  by 
Transmission  electron microscopy  (TEM)  and  it  is  shown  in  Fig.No.24  confirming  the 
spherical shaped particles in nanometric range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure no 24: TEM images of liposomes 
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6.7  SCANNING ELECTRON MICROSCOPY ( SEM )  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure no 25: SEM images of Cisplatin liposomes 
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DISCUSSION 
 
 
 
 
The Morphology and surface appearance of Liposomes were examined by using 
SEM. The SEM photographs of F2 and F6 formulation showed that the particles have 
smooth surface. The SEM images were shown in figure no: 25. 
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6.8 DETERMINATION OF PERCENTAGE FREE DRUG 
 
Table No: 11 Percent free drug of Cisplatin liposomal solution for F1, F2, F3, 
F4, F5 and F6 Formulations 
 
 
S. No. Formulation code Percentage of free drug 
   
1. F1 45.23
   
2. F2 39.3
   
3. F3 30.20
   
4. F4 25.31
   
5. F5 17.21
   
6. F6 8.72
   
 
 
 
 
 
DISCUSSION 
 
The percent free drug is determined for all the formulations F1 to F6. The 
percent free drug was optimum in F6 formulation, which is within the limit (10%), the 
percent free drug was as shown in the table no: 11. 
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6.9  ASSAY RESULTS  
 
 
 
 
Table No: 12 Assay of Cisplatin liposomal solution for F1, F2, F3, F4, F5, F6 
 
 
 
 
Formulations. 
 
S. No. Formulation code Cisplatin  
   
1. F1 98.8% 
   
2. F2 99.7% 
   
3. F3 95.6% 
 
4. F4 97.3% 
 
5. F5 97.2% 
 
6. F6 98.0 % 
   
 
 
 
 
 
DISCUSSION 
 
The percentage purity is determined for all the formulations from F1to 
F6. The assay value is within the limit (90%) for all the formulations, the results were 
shown in the table no: 12. 
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6.10  IN- VITRO DIFFUSION SYUDIES  
 
 
 
 
Table No.13 Diffusion results of F1 formulation 
 
 
 
 
Time  log Absorbance Conc.   Log Log 
 √time    %CDR %CDRR   
(hr)  time (nm) (µg/2ml)   %CDR %CDRR
     
2 1.414 0.301 0.0032 0.165 1.29 98.71 0.110 1.994
         
4 2 0.602 0.0047 0.3068 2.36 97.64 0.372 1.989
         
6 2.441 0.778 0.0074 0.5616 4.32 95.68 0.635 1.980
         
8 2.828 0.903 0.0092 0.7395 5.65 94.35 0.752 1.974
         
10 3.162 1 0.013 1.108 8.53 91.47 0.930 1.961
         
12 3.464 1.079 0.016 1.457 11.21 88.79 1.049 1.948
         
14 3.741 1.146 0.022 1.982 15.25 84.75 1.183 1.928
         
16 4 1.204 0.027 2.424 18.65 81.35 1.250 1.910
         
18 4.242 1.255 0.037 3.377 25.98 74.02 1.414 1.869
         
20 4.472 1.301 0.048 4.400 33.85 66.15 1.529 1.820
         
22 4.69 1.342 0.067 5.960 45.85 54.15 1.661 1.733
         
24 4.899 1.380 0.069 6.425 49.43 50.57 1.693 1.703
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Table No.14 Diffusion results of F2 formulation 
 
 
    Conc.     
Time  log Absorbance    Log Log% 
 √time   (µg/2m %CDR %CDRR   
(hr)  time (nm)    %CDR CDRR 
    l)     
         
2 1.414 0.301 0.006 0.424 3.26 96.74 0.513 1.985
         
4 2 0.602 0.007 0.537 4.43 95.57 0.646 1.980
         
6 2.441 0.778 0.009 0.707 5.58 94.42 0.746 1.975
         
8 2.828 0.903 0.012 0.99 7.61 92.39 0.881 1.960
         
10 3.162 1 0.015 1.27 9.79 90.21 0.99 1.950
         
12 3.464 1.079 0.0158 1.34 11.37 88.61 1.055 1.947
         
14 3.741 1.146 0.028 2.5 19.23 80.77 1.283 1.907
         
16 4 1.204 0.035 3.16 24.30 75.70 1.385 1.879
         
18 4.242 1.255 0.049 4.48 34.46 65.54 1.537 1.816
         
20 4.472 1.301 0.063 5.8 44.62 55.38 1.649 1.743
         
22 4.69 1.342 0.083 7.68 52.13 47.87 1.717 1.680
         
24 4.899 1.380 0.085 7.90 61 38.34 1.786 1.589
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Table No.15 Diffusion results of F3 formulation 
 
 
Time  log Absorbance Conc.   Log Log 
 √time    %CDR %CDRR   
(hr)  time (nm) (µg/2ml)   %CDR %CDRR
         
2 1.414 0.301 0.0037 0.2145 1.65 98.35 0.217 1.992
         
4 2 0.602 0.0059 0.4173 3.21 96.79 0.506 1.985
         
6 2.441 0.778 0.0084 0.6513 5.01 94.99 0.699 1.977
         
8 2.828 0.903 0.0.053 0.8528 6.56 93.44 0.816 1.970
         
10 3.162 1 0.0105 1.280 9.85 90.15 0.993 1.954
         
12 3.464 1.079 0.0201 1.762 13.56 86.44 1.132 1.936
         
14 3.741 1.146 0.024 2.21 17.04 82.96 1.231 1.918
         
16 4 1.204 0.297 2.66 20.53 79.47 1.312 1.900
         
18 4.242 1.255 0.0423 3.85 29.62 70.38 1.471 1.847
         
20 4.472 1.301 0.0518 4.75 36.56 63.44 1.563 1.802
         
22 4.69 1.342 0.0698 6.44 49.59 50.41 1.695 1.702
         
24 4.899 1.380 0.0812 7.525 57.30 42.11 1.762 1.624
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Table No.16 Diffusion results of F4 formulation 
 
 
Time  log Absorbance Conc.   Log Log 
 √time    %CDR %CDRR   
(hr)  time (nm) (µg/2ml)   %CDR %CDRR
         
2 1.414 0.301 0.007 0.51 3.99 96.01 0.6 1.982
         
4 2 0.602 0.0082 0.632 5.07 94.93 0.705 1.977
         
6 2.441 0.778 0.015 1.27 9.79 90.29 0.987 1.955
         
8 2.828 0.903 0.016 1.367 10.51 89.49 1.021 1.951
         
10 3.162 1 0.018 1.55 11.96 88.04 1.077 1.944
         
12 3.464 1.079 0.02 1.74 13.42 86.58 1.127 1.937
         
14 3.741 1.146 0.036 3.25 25.03 74.97 1.398 1.874
         
16 4 1.204 0.047 4.29 33.01 66.99 1.518 1.826
         
18 4.242 1.255 0.059 5.42 41.72 58.28 1.62 1.765
         
20 4.472 1.301 0.075 6.93 53.30 46.97 1.724 1.671
         
22 4.69 1.342 0.083 7.68 59.30 40.7 1.771 1.609
         
24 4.899 1.380 0.095 8.82 67.84 32.13 1.831 1.506
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 Table No.17 Diffusion results of F5 formulation     
            
 Time   log Absorbance Conc.   Log Log  
  √time     %CDR %CDRR    
 (hr)   time (nm) (µg/2ml)   %CDR %CDRR  
            
 2 1.414  0.301 0.030 0.275 2.12 97.88 0.326 1.990
            
 4 2  0.602 0.007 0.522 4.02 95.98 0.607 1.982  
            
 6 2.441  0.778 0.009 0.795 6.12 93.88 0.786 1.972  
            
 8 2.828  0.903 0.012 1.081 8.32 91.68 0.920 1.962  
            
 10 3.162  1 0.019 1.679 12.92 87.08 1.111 1.939  
            
 12 3.464  1.079 0.025 2.278 17.53 82.47 1.243 1.916  
            
 14 3.741  1.146 0.031 2.78 21.45 78.55 1.331 1.895  
            
 16 4  1.204 0.036 3.295 25.35 74.65 1.403 1.873  
            
 18 4.242  1.255 0.051 4.67 35.95 64.05 1.555 1.806  
            
 20 4.472  1.301 0.063 5.83 44.86 55.14 1.651 1.741  
            
 22 4.69  1.342 0.077 7.182 55.25 44.75 1.743 1.650  
            
 24 4.899  1.380 0.087 8.14 62.64 37.36 1.796 1.572  
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 Table No.18 Diffusion results of F6 formulation     
            
 Time √time  log Absorbance Conc. %CDR %CDRR Log Log  
 (hr)   time (nm) (µg/2ml)   %CDR %CDRR  
            
 2 1.414  0.301 0.005 0.330 2.5 97.5 0.397 1.989
            
 4 2  0.602 0.008 0.613 4.71 95.29 0.673 1.979  
            
 6 2.441  0.778 0.011 0.896 6.89 93.11 0.836 1.968  
            
 8 2.828  0.903 0.017 1.462 11.24 88.76 1.05 1.948  
            
 10 3.162  1 0.019 1.65 12.64 87.31 1.103 1.941  
            
 12 3.464  1.079 0.025 2.21 17.05 82.95 1.231 1.918  
            
 14 3.741  1.146 0.04 3.63 27.9 72.1 1.445 1.857  
            
 16 4  1.204 0.59 5.42 41.72 58.28 1.62 1.765  
            
 18 4.242  1.255 0.73 6.74 51.84 48.16 1.714 1.682  
            
 20 4.472  1.301 0.85 7.87 61.31 38.69 1.787 1.587  
            
 22 4.69  1.342 0.98 9.10 70.02 29.98 1.845 1.476  
            
 24 4.899  1.380 0.120 11.17 85.92 14.08 1.934 1.148  
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dept. of Pharmaceutics,       JKKMMRF College of pharmacy  
96 
Chapter No: 6 Results 
 
 
 100         
 80         
%
CD
R  60         
40                 
 20         
 0         
 0  5 10 15 20 25  30
     Time(hr)    
  f1 f2 f3 f4 f5 f6   
 
 
 
Figure No: 26 In-vitro drug release of F1 to F6 Formulations 
 
 
 
 
 
DISCUSSION 
 
The in-vitro diffusion profile of prepared formulations was carried out by 
membrane diffusion method. The diffusion was carried out for a period of 24 hrs in 
Phosphate buffer pH 7.4. 
 
The cumulative percent release of F1 to F6 formulations at various time intervals 
was calculated and tabulated in table no: 11 to 16. The cumulative percent drug release 
in all formulations was plotted against time in figure no: 26. The Maximum percent of 
drug release was found in F6 formulation which contains maximum drug entrapment. 
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6.11  RELEASE KINETICS  
 
 
 
 
Table No: 19 Curve fitting data of release rate profile of Formulations F1, to F6. 
 
 
 
 
 
 
 
Type of Zero-order First-order Higuchi Korsmeyer – 
     
F1 0.9058 0.8554 0.8089 0.9668 
     
F2 0.9029 0.8473 0.801 0.8938 
     
F3 0.901 0.8331 0.8029 0.9635 
     
F4 0.9234 0.8256 0.8315 0.9094 
     
F5 0.9338 0.8662 0.8453 0.9718 
     
F6 0.9312 0.8013 0.8402 0.9552 
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Figure No: 27 Release kinetics from F1 Formulation 
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Figure No: 28 Release kinetics from F2 Formulation 
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Figure No: 29 Release kinetics from F3 Formulation 
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Figure No: 30 Release kinetics from F4 Formulation 
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Figure No: 31 Release kinetics from F5 Formulation 
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Figure No: 32 Release kinetics from F6 Formulation 
 
 
DISCUSSION 
 
 
The release kinetics of F1 to F6 formulations were studied. All formulations 
follow Zero order release kinetics and follow case II transport when it applied to the 
Korsmeyer-Peppas Model for mechanism of drug release. F6 formulation has better 
kinetic results when compared to other formulations. The results are shown in table no: 
10 to 15 and graph no: 25 to 30. 
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6.12  LYOPHILIZATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure no : 33 Lyophilization process 
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Figure No : 34 Lyophilized formulation of Cisplatin liposomes 
 
 
DISCUSSION 
 
 
The optimized formula was lyophilized for 5-6 trails keeping the liposomal 
suspension at various primary, secondary temperature and 5th trial was optimized and 
optimized sample cake stored at 4
0
c. Results of lyophilized formulation were shown in 
figure no.33,34. 
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6.12 STABILITY STUDIES 
 
 
Table No: 20 Effect of temperature on Assay of Cisplatin at 4
o
c and 
room temperature 
 
 
 
 
 
S. No Days Assay at 4
o
c Assay at room 
   temperature 
    
1 0 98 98% 
    
2 15 97.5% 97.8% 
    
3 30 96.7% 95.9% 
    
4 40 96.2% 92.5% 
    
5 60 95.7% 90.2% 
    
 
 
 
DISCUSSION 
 
 
The stability of the Cisplatin Liposomes was evaluated after storage at 4
0
c and room 
temperature for 60 days. The assays of the samples were determined as a function of the 
storage time. The Liposomes stored at 4
0
c were found to be stable for duration of 60 
days. The results were shown in table no 20. 
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DISCUSSION 
 
 
CALIBRATION CURVE OF CISPLATIN 
 
 
The UV absorbance of Cisplatin standard solution in the range of 10-80 µg/ml of 
drug in phosphate buffer pH 7.4 showed linearity at λ max 301nm. The linearity was 
plotted for absorbance against concentration with R2 value 0.9989 and with the slope 
equation y = 0.0106x + 0.0015. 
PREFORMULATION STUDIES OF CISPLATIN 
 
The compatibility between the drug and the selected lipid and other excipients 
was evaluated using FTIR peak matching method. The percentage correlations were 
evaluated and the results showing that there was no appearance or disappearance of 
peaks in the drug-lipid mixture, which confirmed the absence of any chemical 
interaction between the drug, lipid and other chemicals. 
 
DIFFERENTIAL SCANNING CALORIMETRY (DSC) RESULTS 
 
The DSC curve of pure drug Cisplatin exhibits a sharp endothermic peak at 
320.1°C.The thermogram of drug-lipid mixture displayed endothermic peaks at 32.1°C, 
120.0°C,400.5°C. DSC measurements showed that drug-lipid mixture was having less 
ordered arrangement of crystals, and this was favorable for increasing the drug loading 
capacity. 
 
DETERMINATION OF PARTICLESIZE DISTRIBUTION AND  
POLYDISPERSITY INDEX: 
 
The Liposomes were prepared by dried thin film hydration technique using rotary 
evaporator with drug and carrier (hydrogenated soya phosphatidyl choline).The 
formulation containing Cisplatin were prepared with stabilizer like tocoferol and all other 
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parameters like temperature, vacuum and RPM were kept constant. The particle size 
distribution was analyzed for F2, F6 formulations of Cisplatin Liposomes by wet method. 
 
ZETA POTENTIAL ANALYSIS 
 
 
The zeta potential of the optimized formulation (F6) was found to be -20mV.Zeta 
potential is an important parameter that influences stability. Extremely positive or 
negative zeta potential values cause larger repulsive forces, whereas repulsion between 
particles with similar electric charge prevents aggregation of the particles and thus 
ensures easy redispersion. In case of a combined electrostatic and steric stabilization, a 
minimum zeta potential of ± 20 mV is desirable. 
 
TRANSMISSION ELECTRON MICROSCOPY (TEM): 
 
 
The Morphology and surface appearance of Liposomes were examined by using SEM. 
The SEM photographs of F2 and F6 formulation showed that the particles have smooth 
surface. 
 
DETERMINATION OF PERCENTAGE FREE DRUG 
 
 
The percent free drug is determined for all the formulations F1 to F6. The percent free 
drug was optimum in F6 formulation, which is within the limit (10%), 
 
ASSAY RESULTS 
 
 
The percentage purity is determined for all the formulations from F1to F6. The assay 
value is within the limit (90%) for all the formulations 
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IN- VITRO DIFFUSION SYUDIES 
 
 
The in-vitro diffusion profile of prepared formulations was carried out by 
membrane diffusion method. The diffusion was carried out for a period of 24 hrs in 
Phosphate buffer pH 7.4. 
 
The cumulative percent release of F1 to F6 formulations at various time intervals 
was calculated and tabulated in table no: 11 to 16. The cumulative percent drug release 
in all formulations was plotted against time in figure no: 26. The Maximum percent of 
drug release was found in F6 formulation which contains maximum drug entrapment. 
 
RELEASE KINETICS 
 
 
The release kinetics of F1 to F6 formulations were studied. All formulations follow Zero 
order release kinetics and follow case II transport when it applied to the Korsmeyer-
Peppas Model for mechanism of drug release. F6 formulation has better kinetic results 
when compared to other formulations. 
 
LYOPHILIZATION 
 
 
The optimized formula was lyophilized for 5-6 trails keeping the liposomal suspension at 
various primary, secondary temperature and 5th trial was optimized and optimized 
sample cake stored at 4
0
c. 
 
STABILITY STUDIES 
 
 
The stability of the Cisplatin Liposomes was evaluated after storage at 4
0
c and 
room temperature for 60 days. The assays of the samples were determined as a function 
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of the storage time. The Liposomes stored at 4
0
c were found to be stable for duration of 
 
60 days. 
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SUMMARY & CONCLUSION 
 
 
 
 
 
Cisplatin, is an anticancer drug, belongs to alkylating agents class. Cisplatin is 
commonly used for the treatment of a wide range of cancers, majorly used in testicular 
and ovarian cancers and also in many types of sarcomas and carcinomas. 
 
 
The main objective of this work was designed to prepare and evaluate the Cisplatin 
Liposomes. This formulation can target the site of action with effect of stabilizer on drug 
entrapment efficiency, and to reduce the side effects by formulating pegylated 
Liposomes. This liposomal formulation was formulated using the hydrogenated soya 
phosphatidyl choline and cholesterol which has lesser toxicity. 
 
 
The Liposomes were prepared by dried thin film hydration technique using rotary 
evaporator with drug, carrier, ammonium sulphate and stabilizer. The parameters like 
temperature, vacuum and RPM were maintained accordingly. After preparation, the 
Liposomes were stored in freezed condition, and given for further evaluation. 
 
 
The prepared Liposomes of F1, F2, F3, F4, F5 and F6 formulations were evaluated 
for physical and chemical characteristics like average vesicle size, shape and zeta 
potential. The evaluated batches showed good physicochemical characteristics in F6 
formulation. 
 
 
The  prepared Liposomes of  F1 to F6 were evaluated for % free drug  and 
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Assay, The % Free drug was optimum in F6 formulation when compared to other 
formulations. 
 
 
This developed liposomal drug delivery system was also evaluated for diffusion 
study by phosphate buffer pH7.4 using membrane diffusion method. The release of drug 
from F6 formulation was found to be sustained to certain extent when compared to other 
formulations. 
 
 
 
 
 
The release kinetics of F6 Formulation were optimized. F6formulation follow Case 
II transport when it is applied to the Korsmeyer model for mechanism of drug release. 
F6 formulation has better kinetic results when compared to other formulations. 
 
 
The stability of the Cisplatin Liposomes was evaluated at 4°c and room temperature 
for 60 days. The assay of the samples was determined as a function of the storage at 
different time intervals. The Liposomes stored at 4
o
c were found to be stable for duration 
of two months. 
 
 
From the results of physical characterization, in-vitro evaluation, release kinetics 
and stability studies, it was found that negative charged Liposomes containing Cisplatin 
might be used for the treatment of a testicular and ovarian cancer when compared to the 
normal drug and neutral Liposomes. 
 
 
 
 
Dept. of Pharmaceutics,        JKKMMRF College of pharmacy  
113 
Chapter No: 8 Summary & Conclusion 
 
 
CONCLUSION: 
 
 
 
 
To conclude the liposomal delivery of cisplatin would act as a suitable 
technique to enhance bioavailability of cisplatin than the conventional dosage form. It 
is also confirmed that liposomes will sustain the drug release, from the executed 
experimental results, it could be concluded that the stabilizer and along with 
hydrogenated soya phosphatidyl choline and cholesterol, were suitable carriers for the 
preparation of Cisplatin Liposomes 
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